RankAlpha logo
Back to Rankings

XAIR

Beyond AirF
Nasdaq / Health Care Equipment & Services
Last Price
$2.01-$0.01 (-0.50%)
At close · 2026-11-17
View Chart
Documents
47
Stored
Transcripts
2
Recent loaded
Latest document
2026-11-12
Related article

Document history

Transcripts and related coverage stored for XAIR. Related articles may discuss other companies and are not verified issuer releases.

12 shown
Related articleQuarter not tagged2026-11-12

Beyond Air (XAIR) Q2 2027 Earnings Call Transcript

Motley Fool
Image source: The Motley Fool. Wednesday, Nov. 11, 2026 - Chief Executive Officer - Robert Goodman - Chief Financial Officer - Dan Moorhead Operator: Good afternoon, everyone, and welcome to the Beyond Air Financial Results Call for the quarter ended September 30, 2026. [Operator Instructions] And now I would like to turn the call over to Corey Davis, LifeSci Advisors. Please go ahead. Corey Davis: Thank you, operator. Good afternoon, everyone, and thank you for joining us. Earlier today, we issued a press release announcing the operational highlights and financial results for Beyond Air's quarter ended September 30, 2026. A copy of this press release can be found on our website, beyondair.net, under the news and Events section. Before we begin, I'd like to remind everyone that we will be making comments and various remarks about future expectations, plans, and prospects which constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Beyond Air cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated. We encourage everyone to review the company's filings with the Securities and Exchange Commission, including, without limitation, the company's most recent Form 10-Q and Form 10-K, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Additionally, this conference call is being recorded and will be available for audio rebroadcast on our website, beyondair.net. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, November 11, 2026. Beyond Air undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this call. With that, I'll turn it over to Robert Goodman, Chief Executive Officer of Beyond Air. Bob, go ahead. The floor is yours. Robert Goodman: Thanks, Corey, and good afternoon, everyone. I'm pleased to speak with you today and provide an update on what has been a productive and meaningful period for Beyond Air. With me today is Dan Moorhead, our Chief Financial Officer. I'll begin with an update on our recent activities and commercial execu…Read full document

Image source: The Motley Fool. Wednesday, Nov. 11, 2026 - Chief Executive Officer - Robert Goodman - Chief Financial Officer - Dan Moorhead Operator: Good afternoon, everyone, and welcome to the Beyond Air Financial Results Call for the quarter ended September 30, 2026. [Operator Instructions] And now I would like to turn the call over to Corey Davis, LifeSci Advisors. Please go ahead. Corey Davis: Thank you, operator. Good afternoon, everyone, and thank you for joining us. Earlier today, we issued a press release announcing the operational highlights and financial results for Beyond Air's quarter ended September 30, 2026. A copy of this press release can be found on our website, beyondair.net, under the news and Events section. Before we begin, I'd like to remind everyone that we will be making comments and various remarks about future expectations, plans, and prospects which constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Beyond Air cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated. We encourage everyone to review the company's filings with the Securities and Exchange Commission, including, without limitation, the company's most recent Form 10-Q and Form 10-K, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Additionally, this conference call is being recorded and will be available for audio rebroadcast on our website, beyondair.net. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, November 11, 2026. Beyond Air undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this call. With that, I'll turn it over to Robert Goodman, Chief Executive Officer of Beyond Air. Bob, go ahead. The floor is yours. Robert Goodman: Thanks, Corey, and good afternoon, everyone. I'm pleased to speak with you today and provide an update on what has been a productive and meaningful period for Beyond Air. With me today is Dan Moorhead, our Chief Financial Officer. I'll begin with an update on our recent activities and commercial execution for LungFit PH before turning the call over to Dan to discuss our financial results for the quarter ended September 30, 2026. We'll then open the call for questions. Throughout the third quarter, we continued to focus on positioning the company for its next phase of growth. As we prepare for the planned commercial launch of our second-generation LungFit PH system pending FDA approval, our priorities remain focused on expanding market penetration, deepening relationships with hospitals and health systems, and growing our commercial pipeline while building on the momentum of our first-generation LungFit PH system. These efforts contributed to record quarterly revenue of $2.3 million in the September quarter, up approximately 28% year-over-year and 31% from the June quarter. We achieved this growth while maintaining financial discipline and prioritizing resources to support commercial execution and preparations for the potential launch of the second-generation LungFit PH. Underlying these results is the progress we are making in expanding market penetration and converting hospital interest into signed customer agreements that support recurring revenue over multiple years. Our in-house sales team is building these relationships supported by national GPO agreements that broaden our reach across hospitals and hospital systems. Our U.S. commercial pipeline is expanding, reflecting accelerated demand for our first-generation system and strong receptivity to our technology and the operational efficiencies it offers. We are especially pleased with the pace of new account wins and the rate of renewals, which speak to the acceptance of our innovative technology and delivery of iNO, resulting in exceptional customer satisfaction, which gives us a foundation to build on as we prepare for the potential launch of the second-generation LungFit PH. International distribution is another important opportunity for growth, with partnerships in place covering more than 40 countries, and international sales during the quarter were one of the highest to date. Looking ahead, pending FDA approval, we believe our second-generation system has the potential to substantially expand our market opportunity and accelerate growth. The system is smaller, has reduced weight, simplified operation, longer service intervals, and expanded operational flexibility. Our PMA supplement seeks expanded FDA labeling that would permit use during patient transport by air and ground. Turning to the regulatory process, our PMA supplement for the second generation of LungFit PH remains under FDA review. We remain encouraged by the progress we're making toward completing the remaining steps of the review process. We expect to complete our audit readiness process in mid-December. The system would then remain subject to FDA inspections and final approval. The timing and outcome of these steps remain subject to the FDA's review. We are excited to be at these final steps of the process. As I mentioned a minute ago, the second-generation LungFit adds transport capability. This is important as it will enable us to serve as a single-source nitric oxide provider across routine care and patient transport, which is the current standard across most U.S. hospital systems. This will strengthen our competitive position and support broader adoption of our cylinder-free technology. Turning to another development program within our LungFit platform, LungFit GO received FDA breakthrough device designation during the quarter for the treatment of nontuberculous mycobacterial pulmonary disease, or NTM-PD. We believe this designation underscores a significant unmet need in NTM-PD and builds upon clinical data generated with LungFit GO in this patient population. While we are encouraged by this designation, we do not currently plan to allocate resources to further development of LungFit GO in 2027. Our focus remains on commercial execution for LungFit PH and preparations for the launch of our second-generation system, pending FDA approval. Let me now provide a brief update on our two indirect subsidiaries focused on development programs outside of our core LungFit business. During the September quarter, we entered into a definitive agreement under which UNIVO Pharmaceuticals Industries would acquire our controlling interest in NeuroNOS Israel. The transaction is intended to provide NeuroNOS with dedicated resources, funding, and strategic focus to advance its development programs. In terms of Beyond Cancer, we're evaluating potential development partnerships and other strategic arrangements to support continued advancements of its pipeline, while maintaining Beyond Air's focus and resource allocation on the commercialization of LungFit PH. Before turning the call over to Dan, I want to emphasize how encouraged we are by the progress we're making with the current LungFit PH offering and the foundation we are strengthening for the potential launch of our second-generation system, pending FDA approval. With this progress, we are reaffirming our revenue guidance of $8 million for calendar year 2026, which excludes revenue from the second-generation system. We are also reaffirming our revenue guidance of $16 million to $18 million for calendar year 2027, which includes anticipated revenue from the second-generation system pending FDA approval. With that, I'll turn the call over to Dan for a review of our financial results. Dan? Daniel Moorhead: Thanks, Bob, and good afternoon, everyone. Let me take this time to walk through our financial results for the quarter ended September 30, 2026. Revenue for the quarter was $2.3 million compared with $1.8 million for the same period last year. This represents growth of approximately 28% year-over-year and 31% from the June 2026 quarter. Gross margin for the quarter was approximately 8% compared with negative 16% for the same period last year. Gross profit was $200,000 compared with a gross loss of $300,000 in the prior year quarter. Research and development expenses were $1.6 million compared with $2.5 million for the same period last year. The decrease was primarily attributed to lower costs related to the second-generation LungFit PH as the majority of the development is complete. Selling, general, and administrative expenses were $4.6 million compared with $4.9 million for the same period last year. The decrease was attributed primarily to lower stock-based compensation costs, partially offset by increased salaries in our sales organization as we build out our commercial team. Other expense for the three months ended September 30, 2026, was $2.2 million as compared to other expense of $600,000 for the three months ended September 30, 2025. The increase in expense was attributed primarily to an increase in interest expense and a charge for scrap material. Net loss attributed to common stockholders of Beyond Air for the three months ended September 30, 2026, was $7.8 million, or a loss of $3.76 per basic and diluted share, compared with a net loss of $7.9 million, or a loss of $24.98 per basic and diluted share, for the three months ended September 30, 2025. As of September 30, 2026, we reported cash, cash equivalents, restricted cash, and marketable securities of $18.5 million, which includes $2.7 million of cash held by NeuroNOS, which is shown within current assets held for sale on the balance sheet, and also includes $700,000 held by Beyond Cancer. This total also includes $4.8 million of restricted cash. As a reminder, we are transitioning our fiscal year-end from March 31 to December 31, effective December 31, 2026. We expect to report results for the nine-month transition period ending December 31, 2026, on a Form 10-KT. The revenue guidance Bob discussed is on a calendar year basis. With that, we will now open the call for questions. Operator: [Operator Instructions] And your first question comes from I-Eh Jen with Laidlaw & Company. Yale Jen: Just two. The first one is that in terms of the FDA review, given that you are going -- on the go, suppose you will finish the audit readiness by mid-December. And was there any other things that the FDA may look for or simply just an inspection and then they will make decisions and have a follow-up? Robert Goodman: Yes, it's pretty much just that, Yale. The audit will follow right after we announce our readiness, and as you mentioned, in the middle of December, and nothing that we know that would be in addition to that. So just a standard audit and feedback. Yale Jen: Okay. Given the time and the holidays to come, presumably, would that be the best scenario? FDA make hopefully positive decisions, maybe in the first quarter, maybe even in the early first quarter of next year. Robert Goodman: Yeah, I mean that's up to the FDA, as you know, right? But yeah, we're expecting to have a quick response. We've been communicating with them directly with all of our paperwork, couple of questions back and forth. We've satisfied those questions. So we're in great shape there. It's now just the audit part. And the good news is the audit -- it's a quick audit. Used to be up to a five-day period, but because a lot of it is done via paperwork back and forth for a couple of days, the actual audit's only like a day and a half long. And so once that happens, we expect to hear back from them within a few weeks. And then there's just a signature process. So, yes, to your point in your timeline, that's right around where we're pointing at. Yale Jen: So. Okay. So maybe lastly, your $16 million to $18 million guidance for next year presumably is based on this assumption, or do you anticipate any possible sort of push out, and if that happens, would that impact on the guidance and things? Robert Goodman: Yeah, we're sticking with our $16 million to $18 million, and that includes Gen 2 only in the second, third, and fourth quarter. So we do not have in our guidance Gen 2 revenue in that first quarter. We're not expecting to push anything out. And, yes, in fact, our pipeline has grown really, really dramatically over the last couple of quarters. So we've had a really nice increase with our Gen 1 pipeline as well as our new wins there. So we've been planning on that so that's where our coverage has been along the way, and we're not expecting to be pushing anything out, at least at this point of course. Yale Jen: So you basically built up some cushion in that -- in your guidance? Robert Goodman: Yes. Yes. We built that just to, as we mentioned that a few months ago, is that we didn't want to expect revenue on Day 1, Q1, but we know the pipeline will be able to spill from 1 quarter, you know, Q4 to Q1 with our real strong Gen 1. So we have Gen 2 coming in, like I said, Q2, 3, and 4. Operator: Your next question comes from Frank Takkinen with Lake Street Capital Markets. Please state your question. Frank Takkinen: I was hoping to follow up on your comments, Bob, about some of the record pipeline that you're referencing. Curious if you can put any numbers around that, whether that be kind of percent up year-over-year, quarter-over-quarter, number of units in backlog, just help us understand just how significant that pipeline is right now and when that could start to convert. Robert Goodman: Yes, sure. So our pipeline from Q1 of this year, it's grown close to fourfold. All right, we actually -- it's more than doubled in the U.S., but what we had done is we did a real sanitation from the legacy team with respect to just some old deals and cleaned up a little bit of pipeline, put a little bit more rigor and definition into our pipeline. So we had grown that, so we had taken it down and then we built it up a bit, but we've now more than doubled it since then. And so, yeah, we're at a nice inflection point with respect to the growth there. Was there another part of that question? What was that? Frank Takkinen: Just thoughts around when that could start to translate to revenue. Robert Goodman: Yeah, so we're already starting to see that translation, in fact. We have the range for next year as mentioned for the $16 million to $18 million. And we have our range within Q1 based off of some of the recent wins we have right now. And as far as our pipeline build, we're really bullish around how these deals are going to be converting. In the quarter we're in now, next quarter, we don't have those yet and we can't obviously share, but, yeah, our win rate is growing. It's increasing, and we're expecting to have that conversion reflected. So, yes, it's a nice bump up because there's a couple of aspects or reasons for that, not just the increase in the pipeline, but the fact of the matter is there's less competitors in the field right now, so we're expecting just based off of that to have a higher win rate. Frank Takkinen: Got it. Very helpful. Let's shift over to Gen 2. Once that is through the approval process, how should we think about what is required to get on formulary with the GPOs? I assume the Gen 1 doesn't suffice and you'll have to do some sort of amendment to include the Gen 2, but maybe any clarifying commentary around that would be helpful. Robert Goodman: Yeah, that's just a quick update with the GPOs. They're really used to doing this. So it's really just an extension of what we have. It's nominal as far as time and effort. And then it's just a matter of -- and really that's it. It's a pretty simple process. Frank Takkinen: And then just last one from me, and apologies in advance, this is splitting hairs a little bit. I think in the last conference call, the calendar Q2 conference call, we were talking a fair bit about the audit readiness process, and at least at that point in time, it seemed like it was kind of a near-term event that was going to be complete in a few months, and it feels like that maybe took a little bit longer than anticipated. Any additional color related to maybe what happened there and why that might have taken a little bit longer? Robert Goodman: Yeah, it's not necessarily that it took longer. You know, there's a lot of rigor that's involved with this. You know, you have the install qualification aspects of a build of a product to the operational qualifications, building up to the performance and the process readiness. We didn't underestimate anything. In fact, if anything, we knew where we'd be and it would be in this part of the second half of the year, and we're expecting it to be right around where we're at now. But no, nothing was slowed down or anything like that. Everything actually was just, we did a lot of repeatability testing and a lot more stability testing. We wanted to make sure that all of our testing was tight. And so no, nothing, no surprise. Let's put it that way. Yes. Operator: [Operator Instructions] And your next question comes from Mike King with Rodman & Renshaw. Michael King: Hey guys, thanks for taking the question. I also want to drill down a little bit more on this FDA review process, Bob, that we met with you and Dan a couple of weeks ago. We were discussing the necessity for FDA to get comfortable that the units could be used in ambulances and on helicopters and that kind of thing. Is that still part of it, or is there something new that's arisen, or is this all part of the same process that you're going through with the auditing? Robert Goodman: Yeah, no, nothing's new. That was part of our PMA supplement paperwork build as well as our testing. So we did a lot of testing on altitude testing, so we worked all of that actually months ago. That was part of this process and that's all been documented in part of our paperwork. So that's actually all behind us and this audit part is really just the back end of the high-level assembly assessment and audit. But that's all done. We're completely done with that and we're really happy with how that all worked out. So we're past all that. Michael King: And are there any personnel limitations or other aspects of the device division at FDA that are making turnaround times longer than you would anticipate? Robert Goodman: I don't think so. I mean, what I do know is on the speed side, it's something that's going to bode well for us is that our R&D facility is an hour and a half away from our contract manufacturer. So what ends up happening when you get into the audit phase, often for a situation like this when you're dealing with a medical device, you could have a research and development division that's in California, but the contract manufacturer could be in Massachusetts and then you have to deal with two different audit teams in order to manage that, or it could be an overseas and U.S. location where ours, we're an hour and a half away from each. So this is actually going to, if anything, speed up the audit process because it will be one team. And, again, that day-and-a-half process really is something that works well for us. Michael King: Okay. And then just real quick on the win rate side, can you just talk about what's responsible, what's driving that? Is it the GPO partnerships, the hospitals better understanding of the device, and maybe you can talk a little bit about the win rate. Robert Goodman: Yes, I mean our technology has been really well received and that's what is the ease of use with respect to our product is just really well received. So our customers are really happy with that, they're really happy with how easy it is to use. And that's helping us with win rates because as you start growing your customer base -- and remember, we just started putting this product out a few years ago, the first-generation product. The first year there was a few sites that were using the product and now we have dozens and dozens of hospitals with that many more sites. So we have a couple hundred units that are out there that are being used and we have so many more referenceable customers that are out there that are speaking on our behalf and that's really helping because people are saying, hey, listen, it's not just that this is a real innovative product, it's actually really easy to use on top of being innovative. You know, as you know, this is a drug that's being delivered through a medical device that we're creating out of thin air. And, well, that's all well and good, but if you're not doing that easily for the customer, all that is really kind of a catchy phrase, and we're able to kind of win on both ends there. And that reflects and goes right to the customer, and the customer sees that and that's what's helping our win rates because, as we're getting into conversations with hospital systems that might be across the city or across the state or it might be a respiratory therapist that knows somebody in that hospital across the country, they're calling each other and they're hearing really good things about us. And that's why we're winning. So, yeah, it's pretty good stuff. Michael King: Got you. Also, can you say, I don't know if revenue is still kind of small, so I don't know if it's really relevant right now, but can you say anything about your average ticket size? Is your average sale increasing, or is it more unit volume that is driving the revenues? Robert Goodman: Yeah, so it's two things. It's the volume and it's the international business that's driving our revenue up right now. Our average deal size is about the same, and I could say roughly it's right around $250,000 is the average deal size. We have these deals anywhere from $30,000 to north of $1 million and can go way higher than that, and we're working on a number of larger deals, but the net of it is our average deal size is about $250,000. We do know, when we have our next-generation product, we're going to be competing for much larger deals, which will definitely increase our overall deal size. So our average deal size will be bumping up significantly from $250,000. Our international business is really helping as well as far as revenue because that is immediate recognized revenue. We get direct sales internationally. We get direct sales also in the VA system. We've had a couple of recent wins there as well, and that drops right to the revenue line there, different than, of course, as you know, the U.S. business, which is a subscription model. But yes, that's the net of it. Operator: Thank you, and we have reached the end of the question and answer session. I will now turn the call over to Robert Goodman for closing remarks. Robert Goodman: All right, I want to thank everybody for joining the call today, for all your support and all your interest, and look forward to speaking with everybody next quarter. Have a great night. Thank you. Operator: Thank you. All parties may now disconnect. Before you buy stock in Beyond Air, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Beyond Air wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $341,157!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,037,753!* Now, it's worth noting Stock Advisor's total average return is 834% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of November 11, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Beyond Air (XAIR) Q2 2027 Earnings Call Transcript was originally published by The Motley Fool

Related articleQuarter not tagged2026-11-12

Beyond Air Inc (XAIR) (Q2 2027) Earnings Call Highlights: Record Revenue and FDA Review in Focus

GuruFocus.com
This article first appeared on GuruFocus. - Revenue: Record quarterly revenue of $2.3 million, up ~28% YoY from $1.8 million and 31% from the June 2026 quarter. - Gross Margin: ~8% for the quarter vs. negative 16% in the prior-year period. - Gross Profit: $200,000 vs. a gross loss of $300,000 in the prior-year quarter. - R&D Expenses: $1.6 million vs. $2.5 million prior year, driven by lower second-generation LungFit PH development costs. - SG&A Expenses: $4.6 million vs. $4.9 million prior year, reflecting lower stock-based compensation partly offset by higher sales salaries. - Other Expense: $2.2 million vs. $600,000 prior year, due to higher interest expense and a scrap materials charge. - Net Loss: $7.8 million, or $3.76 per basic and diluted share, vs. $7.9 million, or $24.98 per share, prior year. - Cash Position: $18.5 million in cash, cash equivalents, restricted cash, and marketable securities as of September 30, 2026 (includes $2.7 million held by NeuroNOS, $700,000 held by Beyond Cancer, and $4.8 million restricted cash). - Revenue Guidance: Reaffirmed $8 million for calendar year 2026 (excludes second-generation system) and $16 million$18 million for calendar year 2027 (includes anticipated second-generation revenue pending FDA approval). - Warning! GuruFocus has detected 7 Warning Signs with XAIR. - Is XAIR fairly valued? Test your thesis with our free DCF calculator. Release Date: November 11, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. - Record quarterly revenue of $2.3 million, up approximately 28% year over year and 31% sequentially. - Gross margin improved to approximately 8% from negative 16% in the prior year quarter, with gross profit of $200,000 versus a gross loss of $300,000. - US commercial pipeline has grown close to fourfold from Q1 2026 and more than doubled in the US, with a growing win rate. - Second-generation LungFit PH system, pending FDA approval, offers smaller size, reduced weight, simplified operation, longer service intervals, and expanded operational flexibility including patient transport capability. - International distribution partnerships cover more than 40 countries, and international sales during the quarter were among the highest to date. - Revenue guidance reaffirmed at $8 million for calendar year 2026 and $16 million to $18 million for calendar year…Read full document

This article first appeared on GuruFocus. - Revenue: Record quarterly revenue of $2.3 million, up ~28% YoY from $1.8 million and 31% from the June 2026 quarter. - Gross Margin: ~8% for the quarter vs. negative 16% in the prior-year period. - Gross Profit: $200,000 vs. a gross loss of $300,000 in the prior-year quarter. - R&D Expenses: $1.6 million vs. $2.5 million prior year, driven by lower second-generation LungFit PH development costs. - SG&A Expenses: $4.6 million vs. $4.9 million prior year, reflecting lower stock-based compensation partly offset by higher sales salaries. - Other Expense: $2.2 million vs. $600,000 prior year, due to higher interest expense and a scrap materials charge. - Net Loss: $7.8 million, or $3.76 per basic and diluted share, vs. $7.9 million, or $24.98 per share, prior year. - Cash Position: $18.5 million in cash, cash equivalents, restricted cash, and marketable securities as of September 30, 2026 (includes $2.7 million held by NeuroNOS, $700,000 held by Beyond Cancer, and $4.8 million restricted cash). - Revenue Guidance: Reaffirmed $8 million for calendar year 2026 (excludes second-generation system) and $16 million$18 million for calendar year 2027 (includes anticipated second-generation revenue pending FDA approval). - Warning! GuruFocus has detected 7 Warning Signs with XAIR. - Is XAIR fairly valued? Test your thesis with our free DCF calculator. Release Date: November 11, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. - Record quarterly revenue of $2.3 million, up approximately 28% year over year and 31% sequentially. - Gross margin improved to approximately 8% from negative 16% in the prior year quarter, with gross profit of $200,000 versus a gross loss of $300,000. - US commercial pipeline has grown close to fourfold from Q1 2026 and more than doubled in the US, with a growing win rate. - Second-generation LungFit PH system, pending FDA approval, offers smaller size, reduced weight, simplified operation, longer service intervals, and expanded operational flexibility including patient transport capability. - International distribution partnerships cover more than 40 countries, and international sales during the quarter were among the highest to date. - Revenue guidance reaffirmed at $8 million for calendar year 2026 and $16 million to $18 million for calendar year 2027, with the 2027 guidance including Gen 2 revenue only in Q2, Q3, and Q4, providing a cushion. - LungFit GO received FDA breakthrough device designation for NTM-PD, underscoring significant unmet need. - Net loss attributable to common stockholders was $7.8 million for the quarter, or $3.76 per basic and diluted share. - Other expense increased to $2.2 million from $600,000 in the prior year quarter, driven by higher interest expense and a charge for scrap materials. - Cash, cash equivalents, restricted cash, and marketable securities totaled $18.5 million as of September 30, 2026, which may be insufficient to fund operations through profitability. - Second-generation LungFit PH remains under FDA review, with audit readiness expected mid-December, and timing and outcome of FDA inspection and final approval remain uncertain. - The company does not currently plan to allocate resources to further development of LungFit GO in 2027, despite the breakthrough designation. - Selling, general, and administrative expenses remained high at $4.6 million, partially offset by lower stock-based compensation but increased by higher salaries in the sales organization. - The company is evaluating strategic arrangements for Beyond Cancer and has agreed to sell its controlling interest in NeuroNOS Israel, indicating potential distraction and resource constraints. Q: Given the FDA review timeline and the mid-December audit readiness target, is a positive decision expected in the first quarter of next year, and is there anything beyond the inspection the FDA is looking for? A: CEO Robert Goodman confirmed there is nothing additional beyond a standard audit and feedback. He noted the audit is now only about a day and a half long (down from up to five days) because much of the review is handled via paperwork, and the company expects to hear back within a few weeks followed by a signature process consistent with an early Q1 timeline. Q: Does the $16 million to $18 million revenue guidance for 2027 assume on-time Gen 2 approval, and would a delay push out the guidance? A: CEO Robert Goodman said the guidance stands and notably excludes any Gen 2 revenue in the first quarter Gen 2 is only included in Q2, Q3, and Q4. He added that the Gen 1 pipeline has grown dramatically and provides a cushion, so no push-out is expected. Q: How significant is the record commercial pipeline, and when could it start converting to revenue? A: CEO Robert Goodman said the pipeline has grown close to fourfold since Q1 2026 (more than doubled in the US after a cleanup of legacy deals). Conversion is already underway, with recent wins supporting the Q1 2027 revenue range, and win rates are rising partly because there are fewer competitors in the field. Q: What is driving the improving win rate? A: CEO Robert Goodman attributed it to strong customer reception of the technology's ease of use, a growing base of referenceable customers (dozens of hospitals and a couple hundred units in use), and word-of-mouth referrals among hospital systems and respiratory therapists. Q: Is the FDA's comfort with ambulance and helicopter transport use still part of the review, or has something new arisen? A: CEO Robert Goodman said nothing is new altitude and transport testing was completed months ago and documented in the PMA supplement. The remaining step is the backend audit of high-level assembly assessments, which is essentially complete. Q: Are personnel limitations at the FDA's device division slowing turnaround times? A: CEO Robert Goodman said he does not believe so, and noted a structural advantage: Beyond Air's R&D facility is only 1.5 hours from its contract manufacturer, so a single audit team can cover both sites potentially speeding up the process versus split domestic or overseas locations. Q: What is required to get Gen 2 on GPO formularies once approved will Gen 1 coverage suffice? A: CEO Robert Goodman said it is simply an extension of existing GPO agreements. GPOs are experienced with this process, and it is nominal in time and effort a pretty simple process. Q: Why did the audit readiness process appear to take longer than indicated on the prior call? A: CEO Robert Goodman said nothing was slowed down or underestimated. The process involved extensive rigor installation qualification, operational qualification, performance and process readiness plus additional repeatability and stability testing to ensure tight results. He characterized it as no surprises. Q: What is driving revenue growth higher average deal size or unit volume? A: CEO Robert Goodman said growth comes from volume and international business, with average deal size roughly unchanged at about $250,000 (deals range from ~$30,000 to over $1 million). He expects average deal size to rise significantly with Gen 2, which will compete for much larger deals. Q: How does international business contribute to revenue compared with the US model? A: CEO Robert Goodman said international sales supported by partnerships covering more than 40 countries are immediately recognized as revenue through direct sales, as are direct sales into the VA system. This differs from the US subscription model, and international sales in the quarter were among the highest to date. Q: What were the key financial results for the quarter ended September 30, 2026? A: CFO Daniel Moorhead reported record revenue of $2.3 million, up ~28% year over year and 31% sequentially; gross margin of ~8% versus negative 16% a year ago; R&D of $1.6 million (down from $2.5 million); SG&A of $4.6 million (down from $4.9 million); and a net loss of $7.8 million, or $3.76 per share. Cash, cash equivalents, restricted cash, and marketable securities totaled $18.5 million. Q: What is the status of the non-core subsidiaries, NeuroNOS and Beyond Cancer? A: CEO Robert Goodman said Beyond Air entered a definitive agreement for UNIVO Pharmaceutical Industries to acquire its controlling interest in NeuroNOS Israel, giving that program dedicated resources and strategic focus. For Beyond Cancer, the company is evaluating development partnerships and other strategic arrangements while keeping resources focused on LungFit PH commercialization. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Related articleQuarter not tagged2026-11-12

Beyond Air, Inc. Q2 2027 Earnings Call Summary

Moby
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. - Record quarterly revenue of $2.3 million was driven by expanding market penetration and the conversion of hospital interest into signed, multi-year recurring revenue agreements. - Growth was supported by national GPO agreements that broadened reach across hospital systems and an in-house sales team focused on deepening institutional relationships. - Management attributed high renewal rates and new account wins to the operational efficiencies and ease of use provided by the first-generation LungFit PH technology. - International sales reached one of their highest levels to date, supported by distribution partnerships covering more than 40 countries. - The company is strategically narrowing its focus to the LungFit PH commercial launch by divesting its interest in Neuro-Israel and seeking external partnerships for Beyond Cancer. - Gross margin improved to approximately 8% from negative 16% in the prior year, reflecting progress in commercial execution and resource prioritization. - R&D expenses decreased as the majority of development for the second-generation LungFit PH system is now complete, shifting focus toward commercial readiness. - Calendar year 2027 revenue guidance of $16 million to $18 million assumes the launch of the second-generation system with revenue contributions starting in the second quarter. - The second-generation system is expected to expand the addressable market by serving as a single-source provider for both routine care and patient transport by air and ground. - Management expects to complete the audit readiness process for the second-generation system in mid-December, followed by FDA inspections and final approval steps. - Despite receiving FDA breakthrough device designation for LungFit Go, the company does not plan to allocate development resources to the program in 2027 to preserve focus on LungFit PH. - The company is transitioning its fiscal year end to December 31, effective December 31, 2026, to align reporting with the calendar year. - Entered a definitive agreement to divest controlling interest in Neuro-Israel to Can-Fite BioPharma to provide the subsidiary with dedicated strategic focus. - LungFit Go received FDA breakthrough device designation for the treatment of nont…Read full document

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. - Record quarterly revenue of $2.3 million was driven by expanding market penetration and the conversion of hospital interest into signed, multi-year recurring revenue agreements. - Growth was supported by national GPO agreements that broadened reach across hospital systems and an in-house sales team focused on deepening institutional relationships. - Management attributed high renewal rates and new account wins to the operational efficiencies and ease of use provided by the first-generation LungFit PH technology. - International sales reached one of their highest levels to date, supported by distribution partnerships covering more than 40 countries. - The company is strategically narrowing its focus to the LungFit PH commercial launch by divesting its interest in Neuro-Israel and seeking external partnerships for Beyond Cancer. - Gross margin improved to approximately 8% from negative 16% in the prior year, reflecting progress in commercial execution and resource prioritization. - R&D expenses decreased as the majority of development for the second-generation LungFit PH system is now complete, shifting focus toward commercial readiness. - Calendar year 2027 revenue guidance of $16 million to $18 million assumes the launch of the second-generation system with revenue contributions starting in the second quarter. - The second-generation system is expected to expand the addressable market by serving as a single-source provider for both routine care and patient transport by air and ground. - Management expects to complete the audit readiness process for the second-generation system in mid-December, followed by FDA inspections and final approval steps. - Despite receiving FDA breakthrough device designation for LungFit Go, the company does not plan to allocate development resources to the program in 2027 to preserve focus on LungFit PH. - The company is transitioning its fiscal year end to December 31, effective December 31, 2026, to align reporting with the calendar year. - Entered a definitive agreement to divest controlling interest in Neuro-Israel to Can-Fite BioPharma to provide the subsidiary with dedicated strategic focus. - LungFit Go received FDA breakthrough device designation for the treatment of nontuberculosis mycobacterial pulmonary disease (NTM-PD). - Other expense increased to $2.2 million, primarily due to higher interest expenses and a specific charge for scrap material. - The U.S. commercial pipeline has more than doubled since the first quarter following a rigorous sanitization of legacy leads and increased market demand. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. - Management expects a quick response following the mid-December audit readiness milestone, noting that the physical audit typically lasts only one and a half days. - Communication with the FDA regarding paperwork and preliminary questions has already been satisfied, leaving the audit as the final primary step. - The $16 million to $18 million guidance includes a cushion by excluding second-generation revenue from the first quarter of 2027. - Management expressed confidence that the strong first-generation pipeline will support early-year growth while the second-generation system ramps up in subsequent quarters. - The U.S. pipeline has more than doubled since Q1, which management attributes to a higher win rate resulting from fewer competitors in the field. - Customer referrals between respiratory therapists and hospital systems are increasingly driving new account conversions. - Current average deal size is approximately $250,000, with individual deals ranging from $30,000 to over $1 million. - Management anticipates that the second-generation product will allow them to compete for much larger hospital system contracts, significantly increasing the average deal size.

Related articleQuarter not tagged2026-11-11

Beyond Air Reports Financial Results and Provides Corporate Update for the Quarter Ended September 30, 2026

GlobeNewswire
Record quarterly revenue of $2.3 million, representing approximately 28% year-over-year growth, reflecting continued adoption of first-generation LungFit PH PMA supplement for second-generation LungFit PH system remains under FDA review; transport capability expected to drive greater market penetration, pending approval Reaffirms revenue guidance of $8 million for CY2026 and $16–$18 million for CY2027 Conference call today at 4:30 p.m. ET GARDEN CITY, N.Y., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced financial results for the quarter ended September 30, 2026, and provided a corporate update. "Building on the commercial momentum we are generating with our first-generation LungFit PH system, we believe our second-generation system has the potential to substantially expand our market opportunity and accelerate growth, pending FDA approval," said Robert Goodman, Chief Executive Officer of Beyond Air. "Our US pipeline is now experiencing unprecedented expansion with an acceleration in demand for our first-generation system and high receptivity to our technology and its operational efficiencies, creating a natural demand for our next generation product. We are especially pleased with the pace of new account wins and rate of renewals, which speak to the high level of customer satisfaction with our unique technology – all of which we believe we can leverage into the potential future launch of our second-generation LungFit PH system. Subject to FDA approval, the system is designed to provide a smaller footprint, reduced weight, simplified operation, longer service intervals and expanded operational flexibility. The PMA supplement seeks expanded FDA labeling that would permit use during patient transport by air and ground." Mr. Goodman continued, "We remain encouraged by our active and productive discussions with the FDA and the progress we are making toward completing the remaining steps in the review process for the second-generation LungFit PH system. We expect to complete our audit-readiness process in mid-December, and subject to FDA inspections and final approval thereafter." Recent Financial and Operating Highlights - Reported revenue of $2.3 millio…Read full document

Record quarterly revenue of $2.3 million, representing approximately 28% year-over-year growth, reflecting continued adoption of first-generation LungFit PH PMA supplement for second-generation LungFit PH system remains under FDA review; transport capability expected to drive greater market penetration, pending approval Reaffirms revenue guidance of $8 million for CY2026 and $16–$18 million for CY2027 Conference call today at 4:30 p.m. ET GARDEN CITY, N.Y., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced financial results for the quarter ended September 30, 2026, and provided a corporate update. "Building on the commercial momentum we are generating with our first-generation LungFit PH system, we believe our second-generation system has the potential to substantially expand our market opportunity and accelerate growth, pending FDA approval," said Robert Goodman, Chief Executive Officer of Beyond Air. "Our US pipeline is now experiencing unprecedented expansion with an acceleration in demand for our first-generation system and high receptivity to our technology and its operational efficiencies, creating a natural demand for our next generation product. We are especially pleased with the pace of new account wins and rate of renewals, which speak to the high level of customer satisfaction with our unique technology – all of which we believe we can leverage into the potential future launch of our second-generation LungFit PH system. Subject to FDA approval, the system is designed to provide a smaller footprint, reduced weight, simplified operation, longer service intervals and expanded operational flexibility. The PMA supplement seeks expanded FDA labeling that would permit use during patient transport by air and ground." Mr. Goodman continued, "We remain encouraged by our active and productive discussions with the FDA and the progress we are making toward completing the remaining steps in the review process for the second-generation LungFit PH system. We expect to complete our audit-readiness process in mid-December, and subject to FDA inspections and final approval thereafter." Recent Financial and Operating Highlights - Reported revenue of $2.3 million for the quarter ended September 30, 2026, the highest quarterly revenue in the Company's history, representing approximately 28% growth over the same period last year and 31% growth compared with the quarter ended June 30, 2026. - Executed the Company's enhanced commercial strategy for first-generation LungFit PH, supporting increased adoption of its cylinder-free nitric oxide technology. - Advanced preparations for the potential U.S. commercial launch of the second-generation LungFit PH system, subject to FDA approval. If approved, the Company believes the addition of transport capability would enable Beyond Air to serve as a single-source nitric oxide provider for hospitals and health systems. - Received FDA Breakthrough Device Designation for LungFit GO for the treatment of nontuberculous mycobacterial pulmonary disease (NTM-PD). The Company does not plan to allocate resources to further development of LungFit GO until the commercial launch of second-generation LungFit PH is well established, following FDA approval. - Announced a definitive agreement under which UNIVO Pharmaceutical Industries Ltd. would acquire the Company's controlling interest in NeuroNOS Israel Ltd. The transaction is intended to provide NeuroNOS with dedicated resources, funding and strategic focus to advance its development programs. - Evaluating potential development partnerships and other strategic arrangements to support the continued advancement of Beyond Cancer's pipeline, while maintaining Beyond Air's focus and resource allocation on its commercialization of LungFit PH. Pending Regulatory Milestones - The PMA supplement for the second-generation LungFit PH system, submitted in June 2025, remains under FDA review. Financial Results for the Quarter Ended September 30, 2026 Revenue for the quarter ended September 30, 2026 was $2.3 million, compared with $1.8 million for the same period last year. Research and development expenses for the three months ended September 30, 2026 were $1.6 million as compared to $2.5 million for the three months ended September 30, 2025. The decrease was primarily attributed to lower costs related to the second-generation LungFit PH as the majority of development is complete. Selling, general and administrative expenses for the three months ended September 30, 2026 were $4.6 million as compared to $4.9 million for the three months ended September 30, 2025. The decrease was attributed primarily to decreases in stock-based compensation costs, partially offset by increased salaries in our sales organization as we build out our commercial team. Other expense for the three months ended September 30, 2026 was $2.2 million as compared to other expense of $0.6 million for the three months ended September 30, 2025. The increase in expense was attributed primarily to an increase in the Company's outstanding debt and related interest expense, in addition to a charge for scrapped materials. Net loss attributed to common stockholders of Beyond Air, Inc. for the three months ended September 30, 2026 was $7.8 million, or a loss of $3.76 per basic and diluted share, compared with a net loss of $7.9 million, or a loss of $24.98 per basic and diluted share, for the three months ended September 30, 2025. As of September 30, 2026, the Company reported cash, cash equivalents, restricted cash and marketable securities of $18.5 million, including $2.7 million of cash held by NeuroNos which is included within current assets held for sale on the balance sheet and $0.7 million of cash held by Beyond Cancer. Restricted cash at September 30, 2026 was $4.8 million. Financial Guidance The Company reaffirms its previously issued revenue guidance of $8 million for calendar year 2026, which excludes revenue from the second-generation LungFit PH system. The Company also reaffirms its revenue guidance of $16 million to $18 million for calendar year 2027, which includes anticipated revenue from the second-generation system, pending FDA approval. Conference Call and Webcast Wednesday, November 11, 2026 at 4:30 p.m. ET Domestic: 1-877-407-0784 International: 1-201-689-8560 Conference ID: 13763626 Webcast: A webcast of the live conference call can be accessed by visiting the Events section of the Company's website (click here) or directly (click here). An online replay will be available on the Company's website or via the direct link an hour after the call. As previously announced, and formally approved by the Board of Directors, the Company is transitioning its fiscal year end from March 31 to December 31, effective December 31, 2026. As a result, the Company expects to report financial results for the nine-month transition period ending December 31, 2026 on a Form 10-K/T. About Beyond Air Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. For more information, visit www.beyondair.net. About LungFit Beyond Air's LungFit is a cylinder-free, phasic flow generator and delivery system designated as a medical device by the U.S. Food and Drug Administration (FDA). The ventilator-compatible version of the device can generate NO from ambient air on demand for delivery to the lungs at concentrations ranging from 1 ppm to 80 ppm. The LungFit system could potentially replace large, high-pressure NO cylinders, providing significant advantages in the hospital setting, including greatly reducing inventory and storage requirements, improving overall safety by eliminating NO2 purging steps, and offering other operational benefits. LungFit can also deliver NO at concentrations at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting (e.g., COVID-19, bronchiolitis) and chronic, refractory lung infections in the home setting (e.g., NTM). With the elimination of cylinders, Beyond Air intends to offer NO treatment in the home setting. About Nitric Oxide Nitric Oxide (NO) is a potent molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions. In the airways, NO targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs. Currently, exogenous inhaled NO is used in adult respiratory distress syndrome, post certain cardiac surgeries and persistent pulmonary hypertension of the newborn to treat hypoxemia. Additionally, NO is believed to play a key role in the innate immune system and in vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, including both gram-positive and gram-negative, but also against other diverse pathogens. Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the Company's revenue guidance for calendar year 2026 and 2027; demand for, and hospital adoption of, the Company's LungFit PH systems, including the Company's pipeline, new account wins and renewals; the FDA's review of the Company's PMA supplement for the second-generation LungFit PH system, including the expected timing of completion of the Company's audit-readiness process and FDA inspections, and the potential approval, intended use, transport capability, commercial launch and commercial benefits of that system; the proposed NeuroNOS transaction, its consideration, closing conditions and anticipated benefits; development plans and resource allocation for LungFit GO; potential partnerships or other strategic arrangements for Beyond Cancer; the Company's liquidity, financing needs and ability to continue as a going concern; the Company's ability to scale its infrastructure; and the Company's fiscal year-end transition and expected filing of a transition report on Form 10-K/T. Forward-looking statements may be identified by words such as "anticipate," "believe," "expect," "intend," "plan," "potential," "will," "would," "could," "may," and similar expressions, or by the use of future tense. Because forward-looking statements relate to future events, they are subject to inherent risks and uncertainties, many of which are beyond the Company's control, that could cause actual results to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, the Company's ability to achieve its revenue guidance, which is based on assumptions regarding demand, hospital adoption, pricing, the timing of FDA approval of the second-generation LungFit PH system and other factors that may not be realized; whether the Company completes its audit-readiness process as anticipated; the timing and outcome of FDA inspections and whether the FDA approves the Company's PMA supplement for the second-generation LungFit PH system, including the requested transport labeling, which may not occur in a timely manner or at all; delays in the commercial launch of the second-generation LungFit PH system; the Company's reliance on third-party contract manufacturers; market acceptance of the Company's products and competition in the nitric oxide market; the possibility that the contemplated investment or other conditions to the NeuroNOS transaction are not satisfied, that the transaction does not close or its anticipated benefits are not realized, or that the value of the UNIVO securities is limited; the availability of resources for LungFit GO, the outcome of further clinical development and regulatory review; the Company's ability to secure and complete strategic arrangements for Beyond Cancer; the Company's history of losses and substantial doubt about its ability to continue as a going concern; the Company's ability to obtain the financing necessary to fund its operations and to satisfy its debt obligations as they come due, and the dilution that any equity financing may cause; the Company's ability to maintain the listing of its common stock on The Nasdaq Stock Market; and other risks described in the "Risk Factors" section of Beyond Air, Inc.'s most recent Annual Report on Form 10-K, its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 and subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it is made and, except as required by law, the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. Contacts Investor Relations contact Corey Davis, Ph.D. LifeSci Advisors, LLC [email protected] (212) 915-2577 BEYOND AIR, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (in thousands) | | September 30, 2026 | | | March 31, 2026 | | | (Unaudited) | | | | ASSETS | | | | | | | | Current assets | | | | | | | | Cash and cash equivalents | | $ | 5,397 | | | $ | 6,740 | Marketable securities | | | 5,652 | | | | 4,901 | Restricted cash | | | 4,832 | | | | 5,622 | Accounts receivable, net | | | 1,450 | | | | 1,086 | Inventory, net | | | 1,190 | | | | 1,406 | Other current assets and prepaid expenses | | | 5,083 | | | | 5,012 | Current assets held for sale | | | 3,024 | | | | - | Total current assets | | | 26,628 | | | | 24,767 | | | | | | | | | Licensed right to use technology | | | 915 | | | | 1,018 | Right-of-use lease assets | | | 1,003 | | | | 1,193 | Property and equipment, net | | | 7,632 | | | | 8,249 | Other assets | | | 77 | | | | 158 | TOTAL ASSETS | | $ | 36,255 | | | $ | 35,385 | | | | | | | | | LIABILITIES AND STOCKHOLDERS' EQUITY | | | | | | | | Current liabilities | | | | | | | | Accounts payable | | $ | 2,128 | | | $ | 2,417 | Accrued expenses and other current liabilities | | | 4,094 | | | | 3,372 | Operating lease liability, current portion | | | 211 | | | | 321 | Loans payable, current portion | | | 58 | | | | 401 | Current liabilities held for sale | | | 759 | | | | - | Total current liabilities | | | 7,250 | | | | 6,511 | | | | | | | | | Operating lease liability, net | | | 899 | | | | 1,023 | Long-term debt, net | | | 21,982 | | | | 21,639 | Warrant liability | | | - | | | | 2 | Total liabilities | | | 30,131 | | | | 29,175 | | | | | | | | | Stockholders' equity | | | | | | | | Preferred Stock | | | - | | | | - | Common Stock | | | - | | | | - | Treasury stock | | | (25 | ) | | | (25 | ) Additional paid-in capital | | | 340,604 | | | | 325,588 | Accumulated deficit | | | (335,324 | ) | | | (319,571 | ) Accumulated other comprehensive income | | | 72 | | | | 134 | Total stockholders' equity attributable to Beyond Air, Inc. | | | 5,327 | | | | 6,126 | Non-controlling interest | | | 797 | | | | 84 | Total stockholders' equity | | | 6,124 | | | | 6,210 | TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | | $ | 36,255 | | | $ | 35,385 | BEYOND AIR, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except share and per share data) (UNAUDITED) | | For the Three Months Ended | | | For the Six Months Ended | | | September 30, | | | September 30, | | | 2026 | | | 2025 | | | 2026 | | | 2025 | | | | | | | | | | | | | Revenues | | $ | 2,324 | | | $ | 1,818 | | | $ | 4,092 | | | $ | 3,578 | | | | | | | | | | | | | | | | | Cost of revenues | | | 2,127 | | | | 2,116 | | | | 3,670 | | | | 3,720 | | | | | | | | | | | | | | | | | Gross profit (loss) | | | 197 | | | | (298 | ) | | | 422 | | | | (142 | ) | | | | | | | | | | | | | | | | Operating expenses: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Research and development | | | 1,581 | | | | 2,450 | | | | 3,540 | | | | 5,536 | Selling, general, and administrative | | | 4,591 | | | | 4,913 | | | | 9,469 | | | | 9,600 | Total operating expenses | | | 6,172 | | | | 7,363 | | | | 13,009 | | | | 15,136 | | | | | | | | | | | | | | | | | Loss from operations | | | (5,975 | ) | | | (7,661 | ) | | | (12,587 | ) | | | (15,278 | ) | | | | | | | | | | | | | | | | Other income/(expense): | | | | | | | | | | | | | | | | Dividend/investment income | | | 93 | | | | 59 | | | | 196 | | | | 87 | Interest and finance expense | | | (1,504 | ) | | | (639 | ) | | | (2,996 | ) | | | (1,187 | ) Change in fair value of warrant liability | | | 1 | | | | (1 | ) | | | 2 | | | | 16 | Foreign exchange gain/(loss) | | | 29 | | | | (18 | ) | | | 69 | | | | (59 | ) Loss on extinguishment of debt | | | (252 | ) | | | - | | | | (405 | ) | | | - | Loss on disposal of fixed assets | | | - | | | | (46 | ) | | | (52 | ) | | | (57 | ) Loss on contract manufacturer's inventory obsolescence | | | (567 | ) | | | - | | | | (567 | ) | | | - | Other income | | | - | | | | 48 | | | | 11 | | | | 142 | Total other expense | | | (2,200 | ) | | | (597 | ) | | | (3,742 | ) | | | (1,058 | ) | | | | | | | | | | | | | | | | Loss before income taxes | | | (8,175 | ) | | | (8,258 | ) | | | (16,329 | ) | | | (16,336 | ) | | | | | | | | | | | | | | | | Provision for income taxes | | | - | | | | - | | | | - | | | | - | | | | | | | | | | | | | | | | | Net loss | | $ | (8,175 | ) | | $ | (8,258 | ) | | $ | (16,329 | ) | | $ | (16,336 | ) | | | | | | | | | | | | | | | | Less: net loss attributable to non-controlling interest | | | (357 | ) | | | (318 | ) | | | (576 | ) | | | (705 | ) | | | | | | | | | | | | | | | | Net loss attributable to Beyond Air, Inc. | | $ | (7,818 | ) | | $ | (7,940 | ) | | $ | (15,753 | ) | | $ | (15,631 | ) | | | | | | | | | | | | | | | | Other comprehensive income/(loss), net of tax | | | | | | | | | | | | | | | | Foreign currency translation adjustment | | | (41 | ) | | | 18 | | | | (62 | ) | | | 145 | | | | | | | | | | | | | | | | | Comprehensive loss attributable to Beyond Air, Inc. | | $ | (7,859 | ) | | $ | (7,922 | ) | | $ | (15,815 | ) | | $ | (15,486 | ) | | | | | | | | | | | | | | | | Net basic and diluted loss per share attributable to Beyond Air, Inc. (1) | | $ | (3.76 | ) | | $ | (24.98 | ) | | $ | (11.22 | ) | | $ | (54.95 | ) | | | | | | | | | | | | | | | | Weighted average number of shares of common stock outstanding, basic and diluted (1) | | | 2,078,853 | | | | 317,829 | | | | 1,403,780 | | | | 284,471 | | Prior period results have been adjusted to reflect the one-for-twenty reverse stock split in July 2026

TranscriptFY2027 Q22026-11-11

FY2027 Q2 earnings call transcript

Earnings source - 58 paragraphs
Operator

Good afternoon, everyone, and welcome to the Beyond Air financial results call for the quarter ended September 30, 2026. At this time, participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. Now, I would like to turn the call over to Corey Davis, LifeSci Advisors. Please go ahead.

Corey Davis

Thank you, operator. Good afternoon, everyone, and thank you for joining us. Earlier today, we issued a press release announcing the operational highlights and financial results for Beyond Air's quarter ended September 30, 2026. A copy of this press release can be found on our website, beyondair.net, under the News and Events section. Before we begin, I'd like to remind everyone that we will be making comments and various remarks about future expectations, plans, and prospects, which constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Beyond Air cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated.

Corey Davis

We encourage everyone to review the company's filings with the Securities and Exchange Commission, including, without limitation, the company's most recent Form 10-Q and Form 10-K, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Additionally, this conference call is being recorded and will be available for audio rebroadcast on our website, beyondair.net. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, November 11, 2026. Beyond Air undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this call. With that, I'll turn it over to Robert Goodman, Chief Executive Officer of Beyond Air. Bob, go ahead. The floor is yours.

Robert Goodman

Thanks, Corey, and good afternoon, everyone. I'm pleased to speak with you today and provide an update on what has been a productive and meaningful period for Beyond Air. With me today is Dan Moorhead, our Chief Financial Officer. I'll begin with an update on our recent activities and commercial execution for LungFit PH before turning the call over to Dan to discuss our financial results for the quarter ended September 30, 2026. We'll then open the call for questions. Throughout the third quarter, we continued to focus on positioning the company for its next phase of growth. As we prepare for the planned commercial launch of our second-generation LungFit PH system, pending FDA approval, our priorities remain focused on expanding market penetration, deepening relationships with hospitals and health systems, and growing our commercial pipeline while building on the momentum of our first-generation LungFit PH system.

Robert Goodman

These efforts contributed to record quarterly revenue of $2.3 million in the September quarter, up approximately 28% year-over-year and 31% from the June quarter. We achieved this growth while maintaining financial discipline and prioritizing resources to support commercial execution and preparations for the potential launch of second-generation LungFit PH. Underlying these results is the progress we are making in expanding market penetration and converting hospital interest into signed customer agreements that support recurring revenue over multiple years. Our in-house sales team is building these relationships supported by national GPO agreements that broaden our reach across hospitals and hospital systems. Our U.S. commercial pipeline is expanding, reflecting accelerated demand for our first-generation system and strong receptivity to our technology and operational efficiencies it offers.

Robert Goodman

We are especially pleased with the pace of new account wins and the rate of renewals, which speak to the acceptance of our innovative technology and delivery of iNO, resulting in exceptional customer satisfaction, which gives us a foundation to build on as we prepare for the potential launch of the second-generation LungFit PH. International distribution is another important opportunity for growth. We have partnerships in place covering more than 40 countries, and international sales during the quarter were one of the highest to date. Looking ahead, pending FDA approval, we believe our second-generation system has the potential to substantially expand our market opportunity and accelerate growth. The system is smaller, has reduced weight, simplified operation, longer service intervals, and expanded operational flexibility. Our PMA supplement seeks expanded FDA labeling that would permit use during patient transport by air and ground.

Robert Goodman

Turning to the regulatory process, our PMA supplement for the second-generation LungFit PH remains under FDA review. We remain encouraged by the progress we are making toward completing the remaining steps in the review process. We expect to complete our audit readiness process in mid-December. The system would then remain subject to FDA inspections and final approval. The timing and outcome of these steps remain subject to the FDA's review. We are excited to be at these final steps of the process. As I mentioned a minute ago, the second-generation LungFit adds transport capability. This is important as it will enable us to serve as a single-source nitric oxide provider across routine care and patient transport, which is the current standard across most U.S. hospital systems. This will strengthen our competitive position and support broader adoption of our cylinder-free technology.

Robert Goodman

Turning to another development program within our LungFit platform, LungFit GO received FDA Breakthrough Device Designation during the quarter for the treatment of nontuberculous mycobacterial pulmonary disease, or NTM PD. We believe this designation underscores the significant unmet need to NTM PD and builds upon clinical data generated with LungFit GO in this patient population. While we are encouraged by this designation, we do not currently plan to allocate resources to further development of LungFit GO in 2027. Our focus remains on commercial execution for LungFit PH and preparations for the launch of our second-generation system, pending FDA approval. Let me now provide a brief update on our two indirect subsidiaries focused on development programs outside of our core LungFit business. During the September quarter, we entered into a definitive agreement under which UNIVO Pharmaceutical Industries would acquire our controlling interest in NeuroNOS Israel.

Robert Goodman

The transaction is intended to provide NeuroNOS with dedicated resources, funding, and strategic focus to advance its development programs. In terms of Beyond Cancer, we are evaluating potential development partnerships and other strategic arrangements to support continued advancements of its pipeline while maintaining Beyond Air's focus and resource allocation on the commercialization of LungFit PH. Before turning the call over to Dan, I want to emphasize how encouraged we are by the progress we are making with the current LungFit PH offering and the foundation we are strengthening for the potential launch of our second-generation system, pending FDA approval. With this progress, we are reaffirming our revenue guidance of $8 million for calendar year 2026, which excludes revenue from the second-generation system. We are also reaffirming our revenue guidance of $16 million-$18 million for calendar year 2027, which includes anticipated revenue from the second-generation system, pending FDA approval.

Robert Goodman

With that, I will turn the call over to Dan for a review of our financial results. Dan?

Dan Moorhead

Thanks, Bob, and good afternoon, everyone. Let me take this time to walk through our financial results for the quarter ended September 30th, 2026. Revenue for the quarter was $2.3 million compared with $1.8 million for the same period last year. This represents growth of approximately 28% year-over-year and 31% from the June 2026 quarter. Gross margin for the quarter was approximately 8% compared with negative 16% for the same period last year. Gross profit was $200,000 compared with a gross loss of $300,000 in the prior year quarter. Research and development expenses were $1.6 million compared with $2.5 million for the same period last year. The decrease was primarily attributed to lower costs related to the second-generation LungFit PH, as the majority of the development is complete.

Dan Moorhead

Selling, general, and administrative expenses were $4.6 million compared with $4.9 million for the same period last year. The decrease was attributed primarily to lower stock-based compensation costs, partially offset by increased salaries in our sales organization as we build out our commercial team. Other expense for the three months ended September 30th, 2026, was $2.2 million as compared to other expense of $600,000 for the three months ended September 30th, 2025. The increase in expense was attributed primarily to an increase in interest expense and a charge for scrap materials.

Dan Moorhead

Net loss attributed to common stockholders of Beyond Air for the three months ended September 30, 2026, was $7.8 million, or a loss of $3.76 per basic and diluted share, compared with a net loss of $7.9 million, or a loss of $24.98 per basic and diluted share for the three months ended September 30, 2025. As of September 30, 2026, we reported cash equivalents, restricted cash, and marketable securities of $18.5 million, which includes $2.7 million of cash held by NeuroNOS, which is shown within current assets held for sale on the balance sheet, and also includes $700,000 held by Beyond Cancer. This total also includes $4.8 million of restricted cash. As a reminder, we are transitioning our fiscal year end from March 31 to December 31, effective December 31, 2026.

Dan Moorhead

We expect to report results for the nine-month transition period ending December 31, 2026, on a Form 10-K/T. The revenue guidance Bob discussed is on a calendar year basis. With that, we will now open the call for questions.

Operator

Thank you. At this time, we will begin with the question-and-answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate that your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment, please, while we poll for questions. Your first question comes from Yale Jen with Laidlaw & Company. Please state your question.

Yale Jen

Great. Thanks for taking the questions. Just two. The first one is that in terms of the FDA review, given that they are going to undergo, suppose you will finish the audit readiness by mid-December, was there any other things that the FDA may look for, or simply just an inspection and then they will make decisions and have a follow-up?

Robert Goodman

Yeah, it's pretty much just that, Yale. The audit will follow right after we announce our readiness, and as you mentioned, in the middle of December. Nothing that we know of that would be in addition to that. So just a standard audit and feedback.

Yale Jen

Okay. Just giving the time and giving the holidays to come, presumably, would that be the best scenario, FDA make hopefully a positive decision, maybe in the first quarter, maybe even in the early first quarter of next year?

Robert Goodman

Yeah. I mean, that's up to the FDA, as you know, right?

Yale Jen

Sure.

Robert Goodman

Yeah, we're expecting to have a quick response. We've been communicating with them directly with all of our paperwork, couple of questions back and forth. We've satisfied those questions. So we're in great shape there. It's now just the audit part. The good news is the audit, it's a quick audit. Used to be a up to five-day period, but because a lot of it is done via paperwork back and forth for a couple of days, the actual audit's only like a day and a half long. Once that happens, we expect to hear back from them within a few weeks, and then there's just the signature process. So yeah, to your point and your timeline, that's right around where we're pointing at.

Yale Jen

Okay. Maybe lastly, your $16 million-$18 million guidance for next year, presumably it is based on this assumption, or do you anticipate any possible sort of push out, and if that happens, would that impact on the guidance? Thanks.

Robert Goodman

Yeah, no. We are sticking with our $16 million-$18 million, and that includes Gen 2 only in the second, third, and fourth quarter. We do not have in our guidance Gen 2 revenue in that first quarter. We are not expecting to push anything out. In fact, our pipeline has grown really, really dramatically over the last couple of quarters. We have had a really nice increase with our Gen 1 pipeline as well as our new wins there. We have been planning on that, so that is where our coverage has been along the way. No, and we are not expecting to be pushing anything out, at least at this point, of course. Yeah.

Yale Jen

You basically built up some cushion in your guidance?

Robert Goodman

Yeah, we built that just to. As we mentioned that a few months ago, we did not want to expect revenue on day one, Q1, but we know the pipeline will be able to still from one quarter, Q4 to Q1, with our real strong Gen 1. We have Gen 2 coming in, like I said, Q2, 3, and 4.

Yale Jen

Okay, great. Thanks a lot. I'll get back to the queue.

Robert Goodman

Yeah, you got it.

Operator

Your next question comes from Frank Takkinen with Lake Street Capital Markets. Please state your question.

Frank Takkinen

Great. Thanks for taking the questions. Was hoping to follow up on your comments, Bob, about some of the record pipeline that you're referencing. Curious if you can put any numbers around that, whether that be percent up year-over-year, quarter-over-quarter, number of units in backlog. Just help us understand just how significant that pipeline is right now and when that could start to convert. Thanks.

Robert Goodman

Yeah, sure. Our pipeline from Q1 of this year, it's grown close to fourfold, all right? Actually, it's more than doubled in the U.S. But what we had done is we did a real sanitation from the legacy team with respect to just some old deals and cleaned up a little bit of pipeline, put a little bit more rigor and definition into our pipeline. We had grown that, or so we had taken it down, and then we built it up a bit, but we've now more than doubled it since then. And so yeah, we're at a nice inflection point with respect to the growth there. Was there another part of that question?

Frank Takkinen

Just thoughts around when that could start to translate to revenue.

Robert Goodman

Yeah. We're already starting to see that translation. In fact, we have the range for next year, as mentioned, for the $16 million-$18 million, and we have our range within Q1. Based off of some of the recent wins we have right now and as far as our pipeline build, we're really bullish around how these deals are going to be converting in the quarter we're in now and next quarter. We don't have those yet, and we can't obviously share. Yeah, our win rate is growing. It's increasing, and we're expecting to have that conversion reflected.

Robert Goodman

Yeah, it's a nice bump up because there's a couple of aspects or reasons for that, not just the increase in the pipeline, but the fact of the matter is there's less competitors in the field right now, so we're expecting, just based off of that, to have a higher win rate.

Frank Takkinen

Got it. Very helpful. Was hoping to shift over to Gen 2. Once that is through the approval process, how should we think about what is required to get on formulary with the GPOs? I assume the Gen 1 doesn't suffice, and you'll have to do some sort of amendment to include the Gen 2, but maybe any clarifying commentary around that would be helpful. Thanks.

Robert Goodman

Yeah, that's just a quick update with the GPOs. They're really used to doing this, so it's really just an extension of what we have. It's nominal as far as time and effort, and then it's just a matter of. Really, that's it. It's a pretty simple process.

Frank Takkinen

Okay, fair enough. Then just last one from me, and apologies in advance, this is splitting hairs a little bit. I think in the last conference call, the calendar Q2 conference call, we were talking a fair bit about the audit readiness process, and at least at that point in time, it seemed like it was kind of a near-term event, that that was going to be complete in a few months, and it feels like that maybe took a little bit longer than anticipated. Any additional color related to maybe what happened there and why that might have taken a little bit longer?

Robert Goodman

Yeah, it's not necessarily that it took longer. There's a lot of rigor that's involved with this. You have the installation qualification aspects of a build of a product to the operational qualifications, building up to the performance and the process readiness. We didn't underestimate anything. In fact, we, if anything, we knew where we'd be, and it would be in this part of the second half of the year, and we were expecting it to be right around where we're at now. But no, nothing was slowed down or anything like that. Everything actually was just. We did a lot of repeatability testing and a lot more stability testing. Wanted to make sure that all of our testing was tight. So no, nothing, no surprises, let's put it that way. Yeah.

Frank Takkinen

Okay, great. Thanks for taking the questions.

Robert Goodman

Yeah. You got it.

Operator

Just a reminder to the audience, to ask a question, press star one on your phone. To remove yourself from the queue, press star two. Your next question comes from Mike King with Rodman & Renshaw. Please state your question.

Mike King

Hey, guys. Thanks for taking the question. I also want to drill down a little bit more on this FDA review process, Bob. When we met with you and Dan a couple of weeks ago, we were discussing the necessity for FDA to get comfortable that the units could be used in ambulances and on helicopters and that kind of thing. I mean, is that still part of it, or is there something new that's arisen, or is this all part of the same process that you're going through with the auditing?

Robert Goodman

Yeah, nothing is new. That was part of our PMA supplement paperwork build as well as our testing, so we did a lot of testing on altitude testing. We worked all of that actually months ago. That was part of this process, and that has all been documented in part of our paperwork. That is actually all behind us, and this audit part is really just the back end of the high-level assembly assessments and audit. That is all done. We are completely done with that, and we are really happy with how that all worked out, so we are past all that.

Mike King

Are there any personnel limitations or other aspects of the device division at FDA that are making turnaround times longer than you would anticipate?

Robert Goodman

I do not think so. What I do know is on the speed side, and something that is going to bode well for us, is that our R&D facility is an hour and a half away from our contract manufacturer. What ends up happening when you get into the audit phase, often, for a situation like this when you are dealing with a medical device, you could have a research and development division that is in California, but the contract manufacturer could be in Massachusetts, and then you have to deal with two different audit teams in order to manage that, or it could be an overseas and U.S. location, where ours are, we are an hour and a half away from each.

Robert Goodman

This is actually going to, if anything, speed up the audit process because it will be one team, and again, that day and a half process really is something that works well for us.

Mike King

Okay. Then just real quick on the win rate side, can you just talk about what's responsible, what's driving that? Is it the GPO partnerships, the hospitals, a better understanding of the device? Maybe you can talk a little bit about the win rate.

Robert Goodman

Yeah. I mean, our technology has been really well received, and that's what it is. The ease of use with respect to our product is just really well received. So, our customers are really happy with that. They're really happy with how easy it is to use. That's helping us with win rates because as you start growing your customer base. Remember, we just started putting this product out a few years ago, the first-generation product. The first year, there was a few sites that were using the product, and now we have dozens and dozens of hospitals with that many more sites.

Robert Goodman

So, we have a couple hundred units that are out there that are being used, and we have so many more referenceable customers that are out there that are speaking on our behalf, and that's really helping because people are saying, "Hey, listen, it's not just that this is a real innovative product. It's actually really easy to use on top of being innovative." As you know, this is a drug that's being delivered through a medical device that we're creating out of thin air. Well, that's all well and good, but if you're not doing that easily for the customer, all that is a really kind of a catchy phrase, and we're able to kind of win on both ends there.

Robert Goodman

That reflects and goes right to the customer, and the customer sees that, and that's what's helping our win rates because as we're getting into conversations with hospital systems that might be across the city or across the state, or it might be a respiratory therapist that knows somebody in that hospital across the country, they're calling each other, and they're hearing really good things about us, and that's why we're winning. So, yeah, it's pretty good stuff.

Mike King

Got you. Can you say, I do not know if revenue is still kind of small, so I do not know if it is really relevant right now, but can you say anything about your sort of average ticket size? Is your average sale increasing, or is it more unit volume that is driving the revenues? Thank you.

Robert Goodman

Yeah. It is these two things. It is the volume and it is the international business that is driving our revenue up right now. Our average deal size is about the same, and I could say roughly it is right around $250,000 is the average deal size when we have these deals anywhere from, whatever, $30,000 to north of $1 million, and can go way higher than that. We are working on a number of larger deals, but the net of it is our average deal size, about $250,000.

Robert Goodman

We do know when we have our next-generation product, we are going to be competing for much larger deals, which will definitely increase our overall deal size. Our average deal size will be bumping up, way up from the $250,000. Our international business is really helping as well as far as revenue because that is immediate recognized revenues. We get direct sales internationally.

Robert Goodman

We get direct sales also in the VA system, where we have had a couple of recent wins there as well, and that drops right to the revenue line there, different than, of course, as you know, the U.S. business, which is a subscription model. That is the net of it.

Mike King

Thanks for taking the questions.

Robert Goodman

Yeah, you got it.

Operator

Thank you, and we have reached the end of the question and answer session. I will now turn the call over to Robert Goodman for closing remarks.

Robert Goodman

All right. I want to thank everybody for joining the call today, for all your support, and all your interest, and look forward to speaking with everybody next quarter. Have a great night. Thank you.

Operator

Thank you, all parties. You may now disconnect.

Related articleQuarter not tagged2026-10-29

Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended September 30, 2026

GlobeNewswire

GARDEN CITY, N.Y., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that it will report financial results for its quarter ended September 30, 2026 on Wednesday, November 11, 2026. The Company's management team is scheduled to host a conference call and webcast at 4:30 p.m. Eastern Time (ET) the same day. Conference Call & Webcast Wednesday, November 11th @ 4:30 p.m. ET Domestic: 1-877-407-0784 International: 1-201-689-8560 Conference ID: 13763626 Webcast: A webcast of the live conference call can be accessed by visiting the Events section of the Company's website (click here) or directly (click here). An online replay will be available on the Company's website or via the direct link an hour after the call. About Beyond Air, Inc. Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. For more information, visit www.beyondair.net. CONTACTS: Corey Davis, Ph.D. LifeSci Advisors, LLC [email protected] (212) 915-2577

Related articleQuarter not tagged2026-10-08

Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026

GlobeNewswire
Preliminary revenue of $2.3 million represents the highest quarterly revenue reported, and approximately 30% sequential quarterly growth and 27% growth over the same period last year Performance reflects continued adoption for first-generation LungFit PH; second-generation system remains under FDA review Reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 GARDEN CITY, N.Y., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced preliminary, unaudited revenue of approximately $2.3 million for the quarter ended September 30, 2026. The preliminary revenue represents an increase of approximately 30% compared with the quarter ended June 30, 2026 and 27% compared with the same quarter last year, and reflects the successful rollout of the Company's enhanced commercial execution strategy for LungFit PH. "Our strong revenue growth in the quarter ended September 30, 2026 reflects continued adoption of LungFit PH and the value hospitals see in our cylinder-free nitric oxide technology," said Robert Goodman, Chief Executive Officer of Beyond Air. "Over the years, we have refined our first-generation system through a series of enhancements and improvements for ease of use. The first-generation LungFit PH has established a strong track record of reliable nitric oxide delivery and has become a trusted system among our hospital customers. Our second-generation system remains under review by the FDA, and we expect demand for the LungFit PH platform to increase significantly following FDA approval. We continue to be pleased with the progress we are seeing with the ongoing PMA supplement process. Adding transport capability will qualify Beyond Air as a single source nitric oxide provider, which is the current standard across most U.S. hospital systems." Revenue Guidance for CY2026 and CY2027 The Company reaffirms its previously issued revenue guidance of $8 million for calendar year 2026, which excludes revenue from the second-generation LungFit PH system. The Company also reaffirms its revenue guidance of $16 million to $18 million for calendar year 2027, which includes anticipated revenue from the second-generation system, pending FDA approval…Read full document

Preliminary revenue of $2.3 million represents the highest quarterly revenue reported, and approximately 30% sequential quarterly growth and 27% growth over the same period last year Performance reflects continued adoption for first-generation LungFit PH; second-generation system remains under FDA review Reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 GARDEN CITY, N.Y., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced preliminary, unaudited revenue of approximately $2.3 million for the quarter ended September 30, 2026. The preliminary revenue represents an increase of approximately 30% compared with the quarter ended June 30, 2026 and 27% compared with the same quarter last year, and reflects the successful rollout of the Company's enhanced commercial execution strategy for LungFit PH. "Our strong revenue growth in the quarter ended September 30, 2026 reflects continued adoption of LungFit PH and the value hospitals see in our cylinder-free nitric oxide technology," said Robert Goodman, Chief Executive Officer of Beyond Air. "Over the years, we have refined our first-generation system through a series of enhancements and improvements for ease of use. The first-generation LungFit PH has established a strong track record of reliable nitric oxide delivery and has become a trusted system among our hospital customers. Our second-generation system remains under review by the FDA, and we expect demand for the LungFit PH platform to increase significantly following FDA approval. We continue to be pleased with the progress we are seeing with the ongoing PMA supplement process. Adding transport capability will qualify Beyond Air as a single source nitric oxide provider, which is the current standard across most U.S. hospital systems." Revenue Guidance for CY2026 and CY2027 The Company reaffirms its previously issued revenue guidance of $8 million for calendar year 2026, which excludes revenue from the second-generation LungFit PH system. The Company also reaffirms its revenue guidance of $16 million to $18 million for calendar year 2027, which includes anticipated revenue from the second-generation system, pending FDA approval. The preliminary revenue figure set forth above is unaudited, is based on management's preliminary estimates and information available to the Company as of the date of this press release, and remains subject to the completion of the Company's financial closing procedures and the review of its interim financial statements by its independent registered public accounting firm, which has not audited, reviewed or performed any procedures with respect to the preliminary figure. Actual results may differ materially from the preliminary figure. The Company will report its complete financial results for the quarter ended September 30, 2026 in November 2026. About Beyond Air®, Inc. Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. For more information, visit www.beyondair.net. About LungFit® Beyond Air's LungFit is a cylinder-free, phasic flow generator and delivery system designated as a medical device by the U.S. Food and Drug Administration (FDA). The ventilator-compatible version of the device can generate NO from ambient air on demand for delivery to the lungs at concentrations ranging from 1 ppm to 80 ppm. The LungFit system could potentially replace large, high-pressure NO cylinders, providing significant advantages in the hospital setting, including greatly reducing inventory and storage requirements, improving overall safety by eliminating NO2 purging steps, and offering other operational benefits. LungFit can also deliver NO at concentrations at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting (e.g., COVID-19, bronchiolitis) and chronic, refractory lung infections in the home setting (e.g., NTM). With the elimination of cylinders, Beyond Air intends to offer NO treatment in the home setting. About Nitric Oxide Nitric Oxide (NO) is a potent molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions. In the airways, NO targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs. Currently, exogenous inhaled NO is used in adult respiratory distress syndrome, post certain cardiac surgeries and persistent pulmonary hypertension of the newborn to treat hypoxemia. Additionally, NO is believed to play a key role in the innate immune system and in vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, including both gram-positive and gram-negative, but also against other diverse pathogens. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the Company's preliminary, unaudited revenue for the quarter ended September 30, 2026; the Company's revenue guidance for calendar year 2026 and 2027; demand for, and hospital adoption of, the Company's LungFit PH systems; the FDA's review of the Company's PMA supplement for the second-generation LungFit PH system and the potential approval, intended use and commercial benefits of that system; and the Company's ability to scale its infrastructure. Forward-looking statements may be identified by words such as "anticipate," "believe," "expect," "intend," "plan," "potential," "will," "would," "could," "may," and similar expressions, or by the use of future tense. Because forward-looking statements relate to future events, they are subject to inherent risks and uncertainties, many of which are beyond the Company's control, that could cause actual results to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, the possibility that the Company's final revenue for the quarter ended September 30, 2026 differs from the preliminary figure as a result of the completion of its financial closing procedures, final adjustments or other developments; the Company's ability to achieve its revenue guidance, which is based on assumptions regarding demand, hospital adoption, pricing and other factors that may not be realized; whether the FDA approves the Company's PMA supplement for the second-generation LungFit PH system, which may not occur in a timely manner or at all; market acceptance of the Company's products and competition in the nitric oxide market; the Company's ability to obtain the financing necessary to fund its operations and to satisfy its debt obligations as they come due; the Company's ability to maintain the listing of its common stock on The Nasdaq Stock Market; and other risks described in the "Risk Factors" section of Beyond Air, Inc.'s most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it is made and, except as required by law, the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. CONTACTS: Investor Relations contact Corey Davis, Ph.D. LifeSci Advisors, LLC [email protected] (212) 915-2577

Related articleQuarter not tagged2026-08-14

Beyond Air (XAIR) Q1 2027 Earnings Call Transcript

Motley Fool
Image source: The Motley Fool. Thursday, Aug. 13, 2026 at 8:00 a.m. ET Chief Executive Officer - Robert Goodman Chief Financial Officer - Daniel Moorhead LifeSci Advisors - Corey Davis Operator: Greetings, and welcome to the Beyond Air Financial Results for the quarter ending June 30, 2026. [Operator Instructions] And now I would like to turn the call over to Corey Davis, LifeSci Advisors. Please go ahead. Corey Davis: Thank you, Operator. Good morning, everyone, and thank you for joining us. Earlier today, we issued a press release announcing the operational highlights and financial results for Beyond Air's quarter ended June 30, 2026. A copy of this press release can be found on our website, beyondair.net, under the News and Events section. Before we begin, I'd like to remind everyone that we will be making comments and various remarks about future expectations, plans, and prospects, which constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Beyond Air cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated. We encourage everyone to review the company's filings with the SEC, including, without limitation, the company's most recent Form 10-K and Form 10-Q, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Additionally, this conference call is being recorded and will be available for audio rebroadcast on our website, beyondair.net. Furthermore, the content of this call contains time-sensitive information that is accurate only as of the date of the live broadcast, August 13, 2026. Beyond Air undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this call. With that, I'll turn the call over to Robert Goodman, Chief Executive Officer of Beyond Air. Bob, the floor is yours. Robert Goodman: Thanks, Corey, and good morning, everyone. With me today is Dan Moorhead, our Chief Financial Officer. As we just had our last quarterly call a few weeks ago, I'll keep my prepared remarks fairly brief. Over the past few months, we've been focused on positioning Beyond Air for its next phase of growth. We strengthened our balance she…Read full document

Image source: The Motley Fool. Thursday, Aug. 13, 2026 at 8:00 a.m. ET Chief Executive Officer - Robert Goodman Chief Financial Officer - Daniel Moorhead LifeSci Advisors - Corey Davis Operator: Greetings, and welcome to the Beyond Air Financial Results for the quarter ending June 30, 2026. [Operator Instructions] And now I would like to turn the call over to Corey Davis, LifeSci Advisors. Please go ahead. Corey Davis: Thank you, Operator. Good morning, everyone, and thank you for joining us. Earlier today, we issued a press release announcing the operational highlights and financial results for Beyond Air's quarter ended June 30, 2026. A copy of this press release can be found on our website, beyondair.net, under the News and Events section. Before we begin, I'd like to remind everyone that we will be making comments and various remarks about future expectations, plans, and prospects, which constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Beyond Air cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated. We encourage everyone to review the company's filings with the SEC, including, without limitation, the company's most recent Form 10-K and Form 10-Q, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Additionally, this conference call is being recorded and will be available for audio rebroadcast on our website, beyondair.net. Furthermore, the content of this call contains time-sensitive information that is accurate only as of the date of the live broadcast, August 13, 2026. Beyond Air undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this call. With that, I'll turn the call over to Robert Goodman, Chief Executive Officer of Beyond Air. Bob, the floor is yours. Robert Goodman: Thanks, Corey, and good morning, everyone. With me today is Dan Moorhead, our Chief Financial Officer. As we just had our last quarterly call a few weeks ago, I'll keep my prepared remarks fairly brief. Over the past few months, we've been focused on positioning Beyond Air for its next phase of growth. We strengthened our balance sheet through an up to $30 million financing, regained compliance with Nasdaq's listing requirements, and continue to expand the commercial foundation supporting LungFit PH. Collectively, these actions have strengthened the company's financial position, increased our commercial reach, and enhanced our ability to execute on what we believe is a significant opportunity ahead of us. As we prepare for the planned commercial launch of our second-generation LungFit PH system, pending FDA approval, our priorities are focused on continuing to expand market access, deepen relationships with hospitals and health systems, grow our commercial pipeline, and execute with financial discipline. We believe these efforts will position Beyond Air to drive broader adoption of the LungFit PH while creating a stronger platform for long-term growth. Turning to the financial results, revenue for the quarter ended June 30, 2026, was $1.8 million, which is effectively flat from the March '26 quarter. While revenue remained relatively consistent, we made meaningful progress advancing the commercial and operational initiatives that we believe will support stronger growth as we move through the remainder of the year and prepare for the planned launch of our second-generation LungFit PH system. We continue to execute against several initiatives designed to expand market access and increase commercial adoption. During the quarter, we entered into a national group purchasing agreement with a leading U.S. GPO, becoming the third major national GPO to partner with Beyond Air. Together with our existing agreements with Premier and Vizient, these relationships provide access to a substantial portion of U.S. hospitals and health systems and represent an important component to our commercial strategy. We also continue to expand our global distribution network through new and existing commercial partnerships, further extending LungFit PH's reach into the international markets. Another growth center for the company will be the expansion of our international distribution. We have a number of partnerships already in place that cover more than 40 countries. As a result of our strengthened financial position following the recent equity raise, we're in a better position to support our partners' efforts to bring LungFit PH to market in many of these areas. We look forward to providing updates on these programs as appropriate. As it relates to the Gen II LungFit system in the U.S., which remains under review at the FDA, we continue to believe this to be the most important near-term catalyst for the company. We submitted our PMA supplement to the FDA in June of 2025, and based off of our interactions with the FDA to date, we continue to believe we are on track for a potential approval in the second half of this calendar year, although the timing and outcome of the review remain subject to the FDA approval process. Accordingly, we continue to prepare for a potential commercial launch. We are maintaining a disciplined and focused approach to capital allocation. We continue to dedicate our resources predominantly to LungFit PH. In our press release issued earlier today, we reaffirmed our previously issued revenue guidance of $8 million for calendar 2026, representing approximately 15% growth over calendar year 2025. I think it is worth noting that we're not including any revenue from the second-generation LungFit for 2026. We also reaffirm our previously issued 2027 revenue guidance of $16 million to $18 million, representing more than 110% growth at the midpoint compared with our 2026 guidance. The guidance for 2027 does include revenue from the potential commercial launch for the second-generation LungFit PH system, subject to FDA approval. Looking forward, Beyond Air is approaching an important inflection point. With continued international expansion and planned commercial launch of our second-generation LungFit systems pending approval, we have established a stronger foundation to accelerate commercial execution and drive meaningful revenue over the coming years. With that, I'll turn the call over to Dan for a review of our financial results. Dan? Daniel Moorhead: Thanks, Bob, and good morning, everyone. I'll walk through our financial results for the quarter ended June 30, 2026. Revenue for the quarters ended June 30, 2026, and 2025, was $1.8 million. Gross margin for the quarter ended June 30, 2026, was 13%, compared with gross margin of 9% for the same period last year. This marks our third consecutive quarter of positive gross profit. Research and development expenses for the quarters ended June 30, 2026, were $2 million, compared to $3.1 million for the same period last year. Selling, general, and administrative expenses for the quarter ended June 30, 2026, were $4.9 million, compared with $4.7 million for the same period last year. Other expense for the quarter ended June 30, 2026, was $1.5, million compared with $500,000 for the same period last year. Net loss attributable to common stockholders of Beyond Air for the quarter ended June 30, 2026, was $7.9 million, or a loss of $11 per basic and diluted share, compared with a net loss of $7.7 million, or $30.67 per share, for the same period last year. As of June 30, 2026, we reported cash, cash equivalents, restricted cash, and marketable securities of $15.2 million. Please note, this cash total does not include our recent financing. As Bob previously mentioned, we recently announced a financing for up to $30 million, which provided $10 million in upfront gross proceeds and the potential for up to an additional $20 million upon the exercise of short- and long-term warrants. This financing provides us with the financial flexibility to execute the planned commercial launch of our second-generation LungFit PH in the U.S., pending FDA approval, as well as the international commercial expansion, subject to applicable regulatory approvals. On our last quarterly call, we announced the change in our fiscal year-end from March 31 to December 31. While we are referring to calendar year goals, you may notice our SEC filing will still be on our March 31 fiscal year-end. We will move to calendar year reporting with the SEC subsequent to our December 31, 2026, filing. With that, we will now open the call for questions. Operator: With that, we will now open the call for questions. [Operator Instructions] Our first question comes from Michael King with Rodman & Renshaw. Please proceed with your question. Jillian Weiss: This is Jillian Weiss on the line for Michael King from Rodman & Renshaw. So you mentioned the financing will support the Gen II LungFit PH launch and commercial rollout. Can you give us a little more detail on what the capital will actually be used for and where you expect to see the biggest investment over the next several quarters? Daniel Moorhead: Sure, I can take that. It really is a lot for operations. So what we have going right now is we have the pilots, which are being built on the Gen II device, in the near term, and then upon FDA clearance, we'd be building a lot more devices and gaining commercial steam for 2027 and beyond. So it's really an operations function, but a lot of it is on the device. And then we are obviously in a cash burn position right now, so it will absorb some of that burn during that period as well. Jillian Weiss: And are things starting to pick up on the contracting side, and do you think hospitals may be more willing to spend remaining budgets heading into year-end? Robert Goodman: Yes, we've noticed a lot of pickup with contracting. Actually, our commercial functions really picked up a lot of that pace with a number of different new opportunities in front of us. Pipelines actually doubled over the last five or six months. So as you know, long sales cycle there, yet a lot of really -- a lot of this has picked up. So, yes. Jillian Weiss: Okay, great. Thanks for taking my questions, and congrats on the quarter. Operator: Thank you. Our next question comes from Yale Jen with Laidlaw & Company. Please proceed with your question. Yale Jen: My first question is, any update in terms of the supplement PMA applications? What I meant is that, any interaction with the FDA and any other related stuff? Then I have a follow-up. Robert Goodman: Yes, let me take that one, Dan. So yes, we've had a lot of activity and a lot of progress with the PMA supplement. So we've begun to submit paperwork to the FDA. They're already reviewing the paperwork, as Dan touched on. We're doing a couple of things with our contract manufacturer, finishing up our engineering build and our pilot builds of all the different products that will be validated by the FDA. So that's all part of this slew of paperwork that goes to them, and it all kind of lands on the performance qualification. It'll be a desk audit that the FDA will eventually be doing with us. So all the different paperwork that's needed to go to them is getting to them on time. We're getting really good communication back and forth. I think I had mentioned on the last call, but this is a really good team over at the FDA. Very communicative, they get back to us within minutes or hours, sometimes days if it would typically take weeks, but they're really quick. And we're really positive on the way the process has been going. Yale Jen: So at this point, would that still be things to be submitted, or basically everything is pretty much done except waiting for their decisions? Robert Goodman: No, it's less of the decision piece and more of setting up. The next phase that we're in, and we're in this now, is that it's the audit phase. As they're reviewing the paperwork, they'll decide when the audits take place. There's a few different audits. We're already ready for a couple of those. And once our final pilot builds are done, which are happening now, we're doing that, then that part of the process will be dropped into their audit queue and their teams will come in and do their audits with us. But yes, we're where we should be and they've received pretty much everything they need to receive. There's always a little back and forth, but not a back and forth that's setting us back. It's more of a, 'Hey, can you furnish us this?' 'oh, yes, that was in document A.' So, yes, everything's where it should be. Yale Jen: Maybe just follow up on that, which is that given we are already in the midst of the third quarter right now, so should we really expect the potential decision likely be in the fourth quarter? Robert Goodman: Yes, you know, I mean, what we're trying not to do is pinpoint an exact date. Only, Yale, the only reason for that, as you know, is it's not like with pharmaceuticals where you have a PDUFA date. Right, it's a medical device, we have to give a range. And yes, to your point, yes, we're now a month into Q3, so likely that would be a Q4 period. We're still in H2, and yes, if you want to try to figure out whether it be in Q3 or Q4, that's up to the FDA and how they're processing everything. So I guess let me step back and just say it's still going to be in H2, but we're only a month and a half away from Q4. Yale Jen: Great. Maybe the last question, which is slightly different from the earlier one, which is that, given that the guidance you have $8 million to $10 million revenues for this year, the calendar '26, so a majority of them will come from the second half, which is starting this quarter. And just curious, what are the confidence at this point to support you feel that the second half will be -- have a greater revenue growth versus the first half? Robert Goodman: Yes, so a couple of pieces on that, and Dan can definitely weigh in as well. But no, not $8 million to $10 million. The guidance was $8 million for this year. And so we're looking, really it's, if we could roll in about $3.7 million in H1, that means around $4.3 million in H2, and we're very confident that we'll be hitting that number. And the reason being is the pipeline that I referred to earlier. We've already started to see wins come in the quarter we're in right now, which will have some impact on the H2 numbers. And then in addition to that, our international is starting to pick up a little bit, which is good. And that's immediate revenue recognition, as you know, because those are all being purchased. And then under our subscription model, where if you grab $1 million of business, it's not spread out over 12 months, and if we close that deal in November, you're really only getting a couple of hundred thousand dollars, you get the whole $1 million, right? So we have a lot of tenders that we have our hands firmly around. We have already won a number of opportunities within this quarter that we know will be seeing that bump up as well. So, yes, we're reaffirming certainly the $8 million and we're also firmly standing behind our 2027 guidance. So, yes, I hope that answers that. Yale Jen: That's very helpful. I appreciate it. And best of luck going forward. And thanks. Operator: We have reached the end of our question-and-answer session. I would now like to turn the floor back over to Robert Goodman for closing comments. Robert Goodman: I just want to thank everybody for joining the call this morning and for all your support. And we look forward to continuing to provide feedback and updates, and look forward to our next call together. Have a great day. Operator: This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation. Before you buy stock in Beyond Air, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Beyond Air wasn’t one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $400,209!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,375,393!* That performance is why people listen. With a track record of beating the S&P 500 by 4x, Stock Advisor offers a distinct advantage. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built for the long haul. See the 10 stocks » *Stock Advisor returns as of August 13, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Beyond Air (XAIR) Q1 2027 Earnings Call Transcript was originally published by The Motley Fool

Related articleQuarter not tagged2026-08-13

Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update

GlobeNewswire
Reports $1.8 million revenue for quarter ended June 30, 2026; reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 PMA supplement for second-generation LungFit PH system under FDA review; approval expected in 2H CY2026 Recent financing up to $30.1 million to support ongoing international expansion and U.S. commercial launch of second-generation LungFit PH system, pending regulatory approval Conference call today at 8:00 a.m. ET GARDEN CITY, N.Y., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced financial results for the quarter ended June 30, 2026, and provided a corporate update. "Over the past several months, we have been focused on strengthening every aspect of the business in advance of our next phase of commercial growth," said Robert Goodman, Chief Executive Officer of Beyond Air. "We strengthened our balance sheet with an up to $30 million financing, and continued to build our commercial infrastructure, customer relationships and sales pipeline. We believe these efforts position us well for the anticipated launch of our second-generation LungFit PH system, pending FDA approval, and support our objective of expanding adoption of LungFit PH over the long term." Recent Financial and Operating Highlights Entered into a national group purchasing agreement with a leading U.S. group purchasing organization (GPO), marking the third major U.S. GPO to engage Beyond Air and expanding the Company’s reach by nearly 2,000 U.S. hospitals and health systems. Regained compliance with Nasdaq’s minimum bid price requirement. Continued to expand the Company's global distribution network for LungFit PH, which now covers more than 45 countries positioning the Company for continued international commercial expansion, subject to applicable regulatory approvals. Pending Regulatory Milestones Awaiting FDA review of the PMA supplement for the second-generation LungFit PH system, submitted in June 2025. International submissions for LungFit PH remain on track with local partners. Financial Results for the Quarter Ended June 30, 2026 Revenues for the quarters ended June 30, 2026 and 2025 were $1.8 million. Gross margins for the quarter ended J…Read full document

Reports $1.8 million revenue for quarter ended June 30, 2026; reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 PMA supplement for second-generation LungFit PH system under FDA review; approval expected in 2H CY2026 Recent financing up to $30.1 million to support ongoing international expansion and U.S. commercial launch of second-generation LungFit PH system, pending regulatory approval Conference call today at 8:00 a.m. ET GARDEN CITY, N.Y., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced financial results for the quarter ended June 30, 2026, and provided a corporate update. "Over the past several months, we have been focused on strengthening every aspect of the business in advance of our next phase of commercial growth," said Robert Goodman, Chief Executive Officer of Beyond Air. "We strengthened our balance sheet with an up to $30 million financing, and continued to build our commercial infrastructure, customer relationships and sales pipeline. We believe these efforts position us well for the anticipated launch of our second-generation LungFit PH system, pending FDA approval, and support our objective of expanding adoption of LungFit PH over the long term." Recent Financial and Operating Highlights Entered into a national group purchasing agreement with a leading U.S. group purchasing organization (GPO), marking the third major U.S. GPO to engage Beyond Air and expanding the Company’s reach by nearly 2,000 U.S. hospitals and health systems. Regained compliance with Nasdaq’s minimum bid price requirement. Continued to expand the Company's global distribution network for LungFit PH, which now covers more than 45 countries positioning the Company for continued international commercial expansion, subject to applicable regulatory approvals. Pending Regulatory Milestones Awaiting FDA review of the PMA supplement for the second-generation LungFit PH system, submitted in June 2025. International submissions for LungFit PH remain on track with local partners. Financial Results for the Quarter Ended June 30, 2026 Revenues for the quarters ended June 30, 2026 and 2025 were $1.8 million. Gross margins for the quarter ended June 30, 2026 were 13%, compared to 9% for the same period last year. Research and development expenses for the quarter ended June 30, 2026 were $2.0 million, compared with $3.1 million for the same period last year. Selling, general and administrative expenses for the quarter ended June 30, 2026 were $4.9 million, compared with $4.7 million for the same period last year. Other expense for the quarter ended June 30, 2026 was $1.5 million, compared with $0.5 million for the same period last year. Net loss attributable to common stockholders of Beyond Air, Inc. for the quarter ended June 30, 2026 was $7.9 million, or a loss of $11.00 per basic and diluted share, compared with a net loss of $7.7 million, or $30.67 per share, for the same period last year. As of June 30, 2026, the Company reported cash, cash equivalents, restricted cash and marketable securities of $15.2 million. Subsequent to quarter-end, the Company strengthened its balance sheet with an up to $30.1 million financing, consisting of $10.2 million in upfront gross proceeds and up to an additional $20.0 million from the potential exercise of short- and long-term warrants, including $10.0 million tied to FDA approval of the second-generation LungFit PH system. The financing was led by certain institutional healthcare investors, with additional participation from certain of the Company's directors and executive officers. Financial Guidance The Company reaffirms its previously issued revenue guidance of $8 million for calendar year 2026, which does not include any revenue from the second-generation LungFit PH system. The Company also reaffirms its previously issued 2027 revenue guidance of $16-$18 million, representing more than 110% year-over-year growth at the midpoint compared with 2026 guidance and includes anticipated revenue from the second-generation LungFit PH system, pending regulatory approval. The Company believes it is entering an important new phase of commercial execution and a potential inflection point for revenue growth, supported by expanding market access, growing customer adoption, international expansion and a significantly larger addressable market pending the commercial launch of the second-generation LungFit PH. Conference Call & Webcast Thursday, August 13, 2026 @ 8 a.m. ET Domestic: 1-877-407-0784 International: 1-201-689-8560 Conference ID: 13762077 Webcast: A webcast of the live conference call can be accessed by visiting the Events section of the Company’s website (click here) or directly (click here). An online replay will be available on the Company’s website or via the direct link an hour after the call. As previously announced, and formally approved by the Board of Directors, the Company is transitioning its fiscal year end from March 31 to December 31, effective December 31, 2026. As a result, the Company expects to report financial results for the nine-month transition period ending December 31, 2026 on a Form 10-K/T. About Beyond Air®, Inc. Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. For more information, visit www.beyondair.net. About LungFit Beyond Air's LungFit is a cylinder-free, phasic flow generator and delivery system designated as a medical device by the U.S. Food and Drug Administration (FDA). The ventilator-compatible version of the device can generate NO from ambient air on demand for delivery to the lungs at concentrations ranging from 1 ppm to 80 ppm. The LungFit system could potentially replace large, high-pressure NO cylinders, providing significant advantages in the hospital setting, including greatly reducing inventory and storage requirements, improving overall safety by eliminating NO2 purging steps, and offering other operational benefits. LungFit can also deliver NO at concentrations at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting (e.g., COVID-19, bronchiolitis) and chronic, refractory lung infections in the home setting (e.g., NTM). With the elimination of cylinders, Beyond Air intends to offer NO treatment in the home setting. Beyond Air's LungFit PH is approved for commercial use in the United States, European Union, and many other countries around the world. Beyond Air's other LungFit systems are not approved for commercial use and are for investigational use only. Beyond Air is not suggesting NO use over 80 ppm or use at home. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the Company’s expectations related to commercial growth, market adoption of LungFit PH, expansion of the Company’s global distribution network andexpansion in the U.S. and international markets, the Company’s ability to maintain compliance with Nasdaq’s continued listing requirements, including compliance with the terms of the Discretionary Panel Monitor, , the timing and outcome of FDA review of the PMA supplement for the second-generation LungFit PH system and the anticipated timing of its commercial launch, the use of the proceeds from, and the potention exercise of warrants issued in connection with, the Company’s recent financing, the Company’s transition of its fiscal year end from March 31 to December 31 and the timing and content of its related transition report on Form 10-K/T, revenue guidance for calendar years 2026 and 2027, and the Company’s long-term strategic and financial performance. Forward-looking statements may be identified by words such as "anticipate," "believe," "expect," "intend," "plan," "potential," "will," "would," "could," "may," and similar expressions, or by the use of future tense. Because forward-looking statements relate to future events, they are subject to inherent risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks related to the Company’s ability to maintain compliance with Nasdaq’s continued listing requirements, including satisfying the terms of the one-year Discretionary Panel Monitor; the Company’s ability to complete its fiscal year-end transition and related regulatory filings in a timely manner; the timing and outcome of FDA review of the PMA supplement for the second-generation LungFit PH system and the Company’s ability to realize the anticipated benefits of its recent financing, including the risk that warrants may not be exercised; dilution to existing stockholders from the issuance of securities in the financing and any warrant exercises; the Company’s ability to successfully execute its commercial strategy, expand its distribution network and GPO relationships and achieve its revenue guidance; and other risks described in the "Risk Factors" section of Beyond Air, Inc.’s most recent Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q and other subsequent filings with the Securities and Exchange Commission. CONTACTS: Investor Relations contactCorey Davis, Ph.D.LifeSci Advisors, [email protected](212) 915-2577 (1)   Prior period results have been adjusted to reflect the one-for-twenty stock split in July 2026.

Related articleQuarter not tagged2026-08-13

Beyond Air Inc (XAIR) (Q1 2027) Earnings Call Highlights: Strategic Financing and Pipeline ...

GuruFocus.com
This article first appeared on GuruFocus. Revenue: $1.8 million for the quarter ended June 30, 2026, effectively flat compared to the March 2026 quarter and the same period last year. Gross Margin: 13% for the quarter, up from 9% in the year-ago period, marking the third consecutive quarter of positive gross profit. Research and Development Expenses: $2.0 million for the quarter, down from $3.1 million in the same period last year. Selling, General, and Administrative Expenses: $4.9 million for the quarter, compared to $4.7 million in the year-ago period. Other Expense: $1.5 million for the quarter, compared to $500,000 in the same period last year. Net Loss: $7.9 million, or $11.00 per basic and diluted share, compared to a net loss of $7.7 million, or $30.67 per share, in the prior-year quarter. Cash Position: $15.2 million in cash, cash equivalents, restricted cash, and marketable securities as of June 30, 2026, excluding the recent up to $30 million financing. Revenue Guidance: Reaffirmed calendar 2026 revenue guidance of $8 million (approximately 15% growth over 2025) and 2027 revenue guidance of $16 million to $18 million (over 110% growth at the midpoint). Warning! GuruFocus has detected 7 Warning Signs with XAIR. Is XAIR fairly valued? Test your thesis with our free DCF calculator. Release Date: August 13, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Beyond Air Inc (NASDAQ:XAIR) strengthened its balance sheet with an up to $30 million financing, providing $10 million in upfront proceeds and potential for additional $20 million from warrants. The company regained compliance with Nasdaq's listing requirements, reducing regulatory and listing risks. Beyond Air Inc (NASDAQ:XAIR) secured a third national group purchasing agreement with a leading US GPO, expanding market access to a substantial portion of US hospitals alongside Premier and Vizient. The company's global distribution network now covers more than 40 countries, with plans to support international partners' market entry. Gross margin improved to 13% from 9% year-over-year, marking the third consecutive quarter of positive gross profit. The commercial pipeline doubled over the last five to six months, indicating growing demand and potential for future revenue growth. Beyond Air Inc (NASDAQ:XAIR) reaffirmed its 2026 revenue guidance of…Read full document

This article first appeared on GuruFocus. Revenue: $1.8 million for the quarter ended June 30, 2026, effectively flat compared to the March 2026 quarter and the same period last year. Gross Margin: 13% for the quarter, up from 9% in the year-ago period, marking the third consecutive quarter of positive gross profit. Research and Development Expenses: $2.0 million for the quarter, down from $3.1 million in the same period last year. Selling, General, and Administrative Expenses: $4.9 million for the quarter, compared to $4.7 million in the year-ago period. Other Expense: $1.5 million for the quarter, compared to $500,000 in the same period last year. Net Loss: $7.9 million, or $11.00 per basic and diluted share, compared to a net loss of $7.7 million, or $30.67 per share, in the prior-year quarter. Cash Position: $15.2 million in cash, cash equivalents, restricted cash, and marketable securities as of June 30, 2026, excluding the recent up to $30 million financing. Revenue Guidance: Reaffirmed calendar 2026 revenue guidance of $8 million (approximately 15% growth over 2025) and 2027 revenue guidance of $16 million to $18 million (over 110% growth at the midpoint). Warning! GuruFocus has detected 7 Warning Signs with XAIR. Is XAIR fairly valued? Test your thesis with our free DCF calculator. Release Date: August 13, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Beyond Air Inc (NASDAQ:XAIR) strengthened its balance sheet with an up to $30 million financing, providing $10 million in upfront proceeds and potential for additional $20 million from warrants. The company regained compliance with Nasdaq's listing requirements, reducing regulatory and listing risks. Beyond Air Inc (NASDAQ:XAIR) secured a third national group purchasing agreement with a leading US GPO, expanding market access to a substantial portion of US hospitals alongside Premier and Vizient. The company's global distribution network now covers more than 40 countries, with plans to support international partners' market entry. Gross margin improved to 13% from 9% year-over-year, marking the third consecutive quarter of positive gross profit. The commercial pipeline doubled over the last five to six months, indicating growing demand and potential for future revenue growth. Beyond Air Inc (NASDAQ:XAIR) reaffirmed its 2026 revenue guidance of $8 million and 2027 guidance of $16-18 million, reflecting confidence in growth trajectory. The FDA review process for the Gen II LungFit PH system is progressing well, with positive communication and timely paperwork submissions, keeping approval on track for H2 2026. Revenue for the quarter ended June 30, 2026, was flat at $1.8 million, showing no growth compared to the prior quarter. The company reported a net loss of $7.9 million for the quarter, with losses per share improving only due to a higher share count. Cash position remains tight at $15.2 million as of June 30, 2026, excluding the recent financing, indicating ongoing cash burn. The FDA approval for the Gen II LungFit PH system is still pending, with no exact timeline, and potential approval is likely pushed to Q4 2026, creating uncertainty. The company's 2026 revenue guidance excludes any contribution from the Gen II system, highlighting reliance on existing products for near-term growth. Other expenses increased significantly to $1.5 million from $500,000 year-over-year, impacting overall financial performance. The company is in a cash burn position, and the recent financing will be used to absorb operational burn, limiting flexibility for other investments. International expansion is still in early stages, with revenue recognition from these markets not yet materializing significantly. Q: Can you provide more detail on what the capital from the recent financing will be used for and where you expect to see the biggest investment over the next several quarters?A: Daniel Moorhead (CFO) stated that the capital will primarily be used for operations, specifically for building pilot devices for the Gen II system in the near term. Upon FDA clearance, the company will scale up device production to gain commercial steam for 2027 and beyond. The funds will also help absorb the company's cash burn during this period. Q: Are things starting to pick up on the contracting side, and do you think hospitals may be more willing to spend remaining budgets heading into year-end?A: Robert Goodman (CEO) confirmed a significant pickup in contracting activity. The commercial pipeline has doubled over the last five to six months, with numerous new opportunities emerging. While sales cycles remain long, the increased pace of activity is a positive indicator for future growth. Q: Any update on the supplement PMA applications and interactions with the FDA?A: Robert Goodman (CEO) reported significant progress with the PMA supplement. The company has submitted the necessary paperwork, and the FDA is currently reviewing it. They are in the audit phase, with pilot builds being finalized. Communication with the FDA has been excellent, with quick response times, and the company is confident in the process. Q: At this point, is everything pretty much done except waiting for the FDA's decision?A: Robert Goodman (CEO) clarified that the process is less about a final decision and more about completing the audit phase. The FDA will schedule audits as they review the paperwork. The company is ready for some audits and is finalizing its pilot builds. They have submitted nearly everything required, with only minor back-and-forth clarifications, and are on track. Q: Given we are in the third quarter, should we expect the potential FDA decision likely in the fourth quarter?A: Robert Goodman (CEO) noted that unlike pharmaceuticals, there is no PDUFA date for medical devices. While the company remains on track for a second-half 2026 approval, he acknowledged that with Q3 already underway, a decision is likely to fall in Q4, depending on the FDA's processing timeline. Q: Given the $8 million revenue guidance for calendar 2026, what gives you confidence that the second half will have greater revenue growth than the first half?A: Robert Goodman (CEO) explained that with approximately $3.7 million in H1 revenue, the company needs around $4.3 million in H2 to hit its target. Confidence is driven by a strong pipeline, early wins in the current quarter, and a pickup in international sales, which provide immediate revenue recognition. The subscription model also allows for full revenue recognition upon closing deals, rather than spreading it out. Q: Can you elaborate on the progress of the international distribution expansion and its impact on revenue?A: Robert Goodman (CEO) highlighted that the company has partnerships covering more than 40 countries. With the strengthened financial position from the recent equity raise, they are better equipped to support partners in bringing LungFit PH to market internationally. This expansion is expected to contribute to revenue growth, with international sales providing immediate revenue recognition. Q: What are the key priorities for the company as it prepares for the commercial launch of the second-generation LungFit PH system?A: Robert Goodman (CEO) stated that the priorities are focused on expanding market access, deepening relationships with hospitals and health systems, growing the commercial pipeline, and executing with financial discipline. These efforts are designed to drive broader adoption of LungFit PH and create a stronger platform for long-term growth. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Related articleQuarter not tagged2026-08-13

Beyond Air, Inc. Q1 2027 Earnings Call Summary

Moby
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management attributed the flat quarter-over-quarter revenue of $1.8 million to the long sales cycles inherent in hospital contracting, while emphasizing that the commercial pipeline has doubled over the last five to six months. The company secured a national group purchasing agreement with a third major U.S. GPO, which management views as a critical strategic component for accessing a substantial portion of U.S. hospitals. Strategic focus has shifted toward international distribution, with partnerships covering more than 40 countries now better supported by a strengthened balance sheet following recent financing. Operational efforts are currently concentrated on the PMA supplement for the second-generation LungFit PH system, which management describes as the most important near-term catalyst for the company. The company maintains a disciplined capital allocation strategy, predominantly dedicating resources to the LungFit PH platform while transitioning its fiscal year-end to December 31 to align with calendar-year reporting. Management noted that the subscription-based revenue model allows for full revenue recognition upon closing deals, providing confidence in meeting back-half targets despite the timing of contract wins. Reaffirmed calendar year 2026 revenue guidance of $8 million, which assumes approximately 15% growth over 2025 and explicitly excludes any revenue contribution from the Gen II system. Projected 2027 revenue of $16 million to $18 million, representing over 110% growth at the midpoint, contingent upon the successful commercial launch of the Gen II LungFit PH system. Management expects a potential FDA approval for the Gen II system in the second half of the calendar year, likely falling in the fourth quarter based on current audit and review progress. Future growth is expected to be driven by a combination of U.S. hospital tender wins and immediate revenue recognition from international equipment purchases. The company anticipates utilizing proceeds from the $30 million financing to fund the build-out of Gen II devices and support operations through the current cash burn phase. Strengthened the balance sheet with a financing agreement for up to $30 million, providing $10 million in upfront gr…Read full document

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management attributed the flat quarter-over-quarter revenue of $1.8 million to the long sales cycles inherent in hospital contracting, while emphasizing that the commercial pipeline has doubled over the last five to six months. The company secured a national group purchasing agreement with a third major U.S. GPO, which management views as a critical strategic component for accessing a substantial portion of U.S. hospitals. Strategic focus has shifted toward international distribution, with partnerships covering more than 40 countries now better supported by a strengthened balance sheet following recent financing. Operational efforts are currently concentrated on the PMA supplement for the second-generation LungFit PH system, which management describes as the most important near-term catalyst for the company. The company maintains a disciplined capital allocation strategy, predominantly dedicating resources to the LungFit PH platform while transitioning its fiscal year-end to December 31 to align with calendar-year reporting. Management noted that the subscription-based revenue model allows for full revenue recognition upon closing deals, providing confidence in meeting back-half targets despite the timing of contract wins. Reaffirmed calendar year 2026 revenue guidance of $8 million, which assumes approximately 15% growth over 2025 and explicitly excludes any revenue contribution from the Gen II system. Projected 2027 revenue of $16 million to $18 million, representing over 110% growth at the midpoint, contingent upon the successful commercial launch of the Gen II LungFit PH system. Management expects a potential FDA approval for the Gen II system in the second half of the calendar year, likely falling in the fourth quarter based on current audit and review progress. Future growth is expected to be driven by a combination of U.S. hospital tender wins and immediate revenue recognition from international equipment purchases. The company anticipates utilizing proceeds from the $30 million financing to fund the build-out of Gen II devices and support operations through the current cash burn phase. Strengthened the balance sheet with a financing agreement for up to $30 million, providing $10 million in upfront gross proceeds to support the Gen II launch. Regained compliance with Nasdaq's listing requirements, stabilizing the company's position in the public markets. Reported a third consecutive quarter of positive gross profit, with gross margin improving to 13% from 9% in the prior year period. Transitioned the corporate fiscal year-end from March 31 to December 31, with formal SEC reporting alignment scheduled to occur after the December 2026 filing. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Management clarified that funds are primarily earmarked for operations and the manufacturing of Gen II pilot devices. A portion of the capital will be used to absorb the current cash burn as the company scales commercial steam for 2027. Management reported high levels of engagement with the FDA, noting that the agency is currently reviewing paperwork and preparing for the audit phase. The process is moving toward a desk audit of performance qualifications once final pilot builds are completed by the contract manufacturer. CEO Robert Goodman expressed high confidence in hitting the $8 million annual target, citing recent contract wins and a doubling of the sales pipeline. The company expects H2 revenue of approximately $4.3 million, supported by international sales and the unique revenue recognition of their subscription model.

TranscriptFY2027 Q12026-08-13

FY2027 Q1 earnings call transcript

Earnings source - 42 paragraphs
Operator

Greetings, and welcome to the Beyond Air financial results for the quarter ending June 30th, 2026. At this time, participants are in a listen-only mode. A Q&A session will follow the formal presentation. I would like to turn the call over to Corey Davis, LifeSci Advisors. Please go ahead.

Corey Davis

Thank you, operator. Good morning, everyone, and thank you for joining us. Earlier today, we issued a press release announcing the operational highlights and the financial results for Beyond Air's quarter ended June 30th, 2026. A copy of this press release can be found on our website, beyondair.net, under the News and Events section. Before we begin, I would like to remind everyone that we will be making comments and various remarks about future expectations, plans, and prospects, which constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Beyond Air cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated.

Corey Davis

We encourage everyone to review the company's filings with the SEC, including, without limitation, the company's most recent Form 10-K and Form 10-Q, which identifies specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Additionally, this conference call is being recorded and will be available for audio rebroadcast on our website, beyondair.net. Furthermore, the content of this call contains time-sensitive information that is accurate only as of the date of the live broadcast, August 13th, 2026. Beyond Air undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this call. With that, I will turn the call over to Robert Goodman, Chief Executive Officer of Beyond Air. Bob, the floor is yours.

Robert Goodman

Thanks, Corey, and good morning, everyone. With me today is Dan Moorhead, our Chief Financial Officer. As we just had our last quarterly call a few weeks ago, I will keep my prepared remarks fairly brief. Over the past few months, we have been focused on positioning Beyond Air for its next phase of growth. We strengthened our balance sheet through an up to $30 million financing, regained compliance with NASDAQ's listing requirements, and continued to expand the commercial foundation supporting LungFit PH. Collectively, these actions have strengthened the company's financial position, increased our commercial reach, and enhanced our ability to execute on what we believe is a significant opportunity ahead of us.

Robert Goodman

As we prepare for the planned commercial launch of our second-generation LungFit PH system, pending FDA approval, our priorities are focused on continuing to expand market access, deepen relationships with hospitals and health systems, grow our commercial pipeline, and execute with financial discipline. We believe these efforts will position Beyond Air to drive broader adoption of the LungFit PH while creating a stronger platform for long-term growth. Turning to the financial results, revenue for the quarter ended June 30th, 2026, was $1.8 million, which is effectively flat from the March 2026 quarter. While revenue remained relatively consistent, we made meaningful progress advancing the commercial and operational initiatives that we believe will support stronger growth as we move through the remainder of the year and prepare for the planned launch of our second-generation LungFit PH system.

Robert Goodman

We continue to execute against several initiatives designed to expand market access and increase commercial adoption. During the quarter, we entered into a national group purchasing agreement with a leading U.S. GPO, becoming the third major national GPO to partner with Beyond Air. Together with our existing agreements with Premier and Vizient, these relationships provide access to a substantial portion of U.S. hospitals and health systems and represent an important component to our commercial strategy. We also continue to expand our global distribution network through new and existing commercial partnerships, further extending LungFit PH's reach into the international markets. Another growth center for the company will be the expansion of our international distribution. We have a number of partnerships already in place that cover more than 40 countries.

Robert Goodman

As a result of our strengthened financial position following the recent equity raise, we are in a better position to support our partners' efforts to bring LungFit PH to market in many of these areas. We look forward to providing updates on these programs as appropriate. As it relates to the Gen 2 LungFit system in the U.S., which remains under review at the FDA, we continue to believe this to be the most important near-term catalyst for the company. We submitted our PMA supplement to the FDA in June of 2025, and based off of our interactions with the FDA to date, we continue to believe we are on track for potential approval in the second half of this calendar year. Although the timing and outcome of the review remain subject to the FDA approval process. Accordingly, we continue to prepare for a potential commercial launch.

Robert Goodman

We are maintaining a disciplined and focused approach to capital allocation. We continue to dedicate our resources predominantly to LungFit PH. In our press release issued earlier today, we reaffirmed our previously issued revenue guidance of $8 million for calendar 2026, representing approximately 15% growth over calendar year 2025. I think it is worth noting that we are not including any revenue from the second-generation LungFit for 2026. We also reaffirm our previously issued 2027 revenue guidance of $16 million-$18 million, representing more than 110% growth at the midpoint compared with our 2026 guidance. The guidance for 2027 does include revenue from the potential commercial launch for the second generation LungFit PH system, subject to FDA approval. Looking forward, Beyond Air is approaching an important inflection point.

Robert Goodman

With continued international expansion and planned commercial launch of our second generation LungFit systems, pending approval, we have established a stronger foundation to accelerate commercial execution and drive meaningful revenue over the coming years. With that, I'll turn the call over to Dan for a review of our financial results. Dan?

Dan Moorhead

Thanks, Bob, and good morning, everyone. I'll walk through our financial results for the quarter ended June 30th, 2026. Revenue for the quarters ended June 30th, 2026 and 2025 was $1.8 million. Gross margin for the quarter ended June 30th, 2026, was 13%, compared with gross margin of 9% for the same period last year. This marks our third consecutive quarter of positive gross profit. Research and development expenses for the quarters ended June 30th, 2026, were $2 million, compared with $3.1 million for the same period last year. Selling, general and administrative expenses for the quarter ended June 30th, 2026, were $4.9 million, compared with $4.7 million for the same period last year. Other expense for the quarter ended June 30th, 2026, was $1.5 million, compared with $500,000 for the same period last year.

Dan Moorhead

Net loss attributable to common stockholders of Beyond Air for the quarter ended June 30th, 2026, was $7.9 million, or a loss of $0.11 per basic and diluted share, compared with a net loss of $7.7 million or $0.3067 per share for the same period last year. As of June 30th, 2026, we reported cash equivalents, restricted cash, and marketable securities of $15.2 million. Please note this cash total does not include our recent financing. As Bob previously mentioned, we recently announced a financing for up to $30 million, which provided $10 million in upfront gross proceeds and the potential for up to an additional $20 million upon the exercise of short and long-term warrants.

Dan Moorhead

This financing provides us with the financial flexibility to execute the planned commercial launch of our second generation LungFit PH in the U.S., pending FDA approval, as well as the international commercial expansion, subject to applicable regulatory approvals. On our last quarterly call, we announced a change in our fiscal year end from March 31st to December 31st. While we are referring to calendar year goals, you may notice our SEC filings will still be on our March 31st fiscal year end. We will move to calendar year reporting with the SEC subsequent to our December 31st, 2026, filing. With that, we will now open the call for questions.

Operator

Thank you. We will now be conducting a Q&A session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate that your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment please while we poll for questions. Our first question comes from Michael King with Rodman & Renshaw. Please proceed with your question.

Jillian Weiss

Hi, everyone. This is Jillian Weiss on the line for Michael King from Rodman & Renshaw. You mentioned the financing will support the Gen 2 LungFit PH launch and commercial rollout. Can you give us a little more detail on what the capital will actually be used for, and where you expect to see the biggest investment over the next several quarters?

Dan Moorhead

Sure. I can take that.

Robert Goodman

Go ahead.

Dan Moorhead

It really is a lot for operations. What we have going right now is we have the pilots, which are being built on the Gen 2 device, in the near term. Then upon FDA clearance, we would be building a lot more devices and gaining commercial steam for 2027 and beyond. It is really an operations function, but a lot of it is on the device. We are obviously in a cash burn position right now, so it will absorb some of that burn during that period as well.

Jillian Weiss

Okay, great. Are things starting to pick up on the contracting side? Do you think hospitals may be more willing to spend remaining budgets heading into year-end?

Robert Goodman

Yeah, we have noticed a lot of pickup with contracting. Actually, our commercial functions really picked up a lot of that pace with a number of different new opportunities in front of us. Pipeline is actually doubled over the last five or six months, so as you know, long sales cycle here.

Robert Goodman

A lot of this has picked up, so yeah.

Jillian Weiss

Okay, great. Thanks for taking my questions, and congrats on the quarter.

Robert Goodman

Thank you.

Dan Moorhead

Thanks.

Operator

Our next question comes from Yale Jen with Laidlaw & Company. Please proceed with your question.

Yale Jen

Good morning, and thanks for taking the questions. My first question is that any update or in terms of the supplement PMA applications? What I meant is that any interaction with FDA and any other related stuff? Then I have a follow-up.

Robert Goodman

Yeah, let me take that one, Dan. We've had a lot of activity and a lot of progress with the PMA supplement. We've begun to submit paperwork to the FDA. They're already reviewing the paperwork. As Dan touched on, we're doing a couple of things with our contract manufacturer, finishing up our engineering build and our pilot builds of all the different products that will be validated by the FDA. That's all part of this slew of paperwork that goes to them, and it all kind of lands on the performance qualification. It'll be a desk audit that the FDA will eventually be doing with us. All the different paperwork that's needed to go to them is getting to them on time. We're getting really good communication back and forth.

Robert Goodman

I think I'd mentioned on the last call, but this is a really good team over at the FDA, very communicative. They get back to us within minutes or hours, sometimes days, if it would typically take weeks, but they're really quick. We're really positive on the way the process has been going.

Yale Jen

At this point, would that still be things to be submitted, or basically everything is pretty much done except waiting for their decisions?

Robert Goodman

No, it's less of the decision piece and more of setting up. The next phase that we're in, and we're in this now, is that it's the audit phase. As they're reviewing the paperwork, they'll decide when the audits take place. There's a few different audits, and we're already ready for a couple of those. Once our final pilot builds are done, which are happening now, we're doing that, then that part of the process will be dropped into their audit queue, and their teams will come in and do their audits with us. But no, we're where we should be, and they've received pretty much everything they need to receive. There's always a little back and forth, but not a back and forth that's setting us back.

Robert Goodman

It's more of a, "Hey, can you furnish us this?" "Oh, yeah, that was in document A." Everything's where it should be.

Yale Jen

Okay, maybe just follow up on that, which is that, given we are already in the midst of the third quarter right now, should we realistically expect the potential decision likely be in the fourth quarter?

Robert Goodman

Yeah. What we're trying not to do is pinpoint an exact date. Only, Yale, the only reason for that is, it's not like with pharmaceuticals where you have a PDUFA date. Since it's a medical device, we have to give a range. Yes, to your point, yeah, we're now a month into Q3, so likely that would be a Q4 period. We're still in H2 and if you were to want to try to figure out would it be in Q3 or Q4, that's up to the FDA and how they're processing everything. I guess let me step back and just say it's still going to be in H2. But we're only a month and a half away from Q4.

Yale Jen

Okay, great. Maybe a last question, which is slightly different from the earlier one, which is that, given that the guidance you have, $8 million-$10 million revenues for this year, calendar 2026. A majority of them will come from the second half, which is starting this quarter. Just curious, what are the confidence at this point to support you feel that the second half will have a greater revenue growth versus the first half? Thanks for taking the questions.

Robert Goodman

Yeah. A couple of pieces on that, and Dan can definitely weigh in as well. But not an $8 million-$10 million. The guidance was $8 million for this year.

Yale Jen

$8 million, I am sorry.

Robert Goodman

Yeah. Really, if we could roll in about $3.7 million in H1, that means around $4.3 million in H2, and we are very confident that we will be hitting that number. And the reason being is the pipeline that I referred to earlier. We have already started to see wins come in the quarter we are in right now, which will have some impact on the H2 numbers. And in addition to that, our international is starting to pick up a little bit, which is good. And that is immediate revenue recognition, as you know, because those are all being purchased and then under our subscription model, where if you grab $1 million of business, it is not spread out over 12 months. If we close that deal in November, you are really only getting a couple of $100,000. You get the whole $1 million, right?

Robert Goodman

We have a lot of tenders that we have our hands firmly around. We have already won a number of opportunities within this quarter that we know will be seeing that bump up as well. So yeah, we are reaffirming certainly the $8 million, and we are also firmly standing behind our 2027 guidance. Yeah, I hope that answers that.

Yale Jen

Okay, great. That's very helpful. I appreciate it, and best luck going forward. Thanks.

Robert Goodman

Yeah, great. Thanks, Yale.

Operator

We have reached the end of our Q&A session. I would now like to turn the floor back over to Robert Goodman for closing comments.

Robert Goodman

I just want to thank everybody for joining the call this morning and for all your support. We look forward to continuing to provide feedback and updates. Look forward to our next call together. Have a great day.

Operator

This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation.

As of 2026-11-14 • Updated weeklySource: Earnings sourceIngestion runbook